Marek's Disease Virus Vaccine Strains

Overview and Taxonomy of Marek's Disease Virus Vaccine Strains

Marek’s disease virus (MDV) represents one of the most economically significant pathogens in global poultry production, causing a lymphoproliferative syndrome characterized by T-cell lymphoma, immunosuppression, paralysis, and visceral tumor formation [1, 15]. The pathogen is classified within the subfamily Alphaherpesvirinae, genus Mardivirus, and is officially designated as Gallid alphaherpesvirus 2 (GaHV-2) by the International Committee on Taxonomy of Viruses (ICTV). The World Organisation for Animal Health (WOAH) lists MD as a notifiable disease due to its profound impact on commercial poultry operations worldwide, with annual economic losses estimated in the billions of dollars. The taxonomy of MDV vaccine strains is inextricably linked to the serological classification of the virus itself, which comprises three distinct serotypes: serotype 1 (GaHV-2), encompassing all pathogenic MDV strains and their attenuated derivatives; serotype 2 (GaHV-3), consisting of naturally non-oncogenic viruses isolated from chickens; and serotype 3 (MeHV-1), the herpesvirus of turkeys (HVT), which is antigenically related but apathogenic in both chickens and turkeys [1, 21]. This tripartite serological framework forms the foundational taxonomy upon which all current vaccine strategies are built.

Serotype 1 Vaccine Strains: The CVI988/Rispens Paradigm

The most widely employed and efficacious serotype 1 vaccine strain is CVI988, commonly known as Rispens, which was developed in the Netherlands through serial passage of a field isolate in chicken embryo fibroblasts (CEFs) [2, 4, 7]. CVI988 is a live attenuated vaccine that retains the capacity to replicate in the host without inducing clinical disease or tumors, yet it confers robust protection against challenge with very virulent (vv) and very virulent plus (vv+) MDV field strains [3, 5, 12]. The molecular basis for its attenuation has been a subject of intensive investigation. Critically, CVI988 harbors unique polymorphisms in the Meq oncoprotein, the primary viral determinant of transformation and tumorigenesis. Specifically, amino acid substitutions at positions 71 (A71S) and 77 (K77E) within the basic region of the Meq bZIP domain drastically impair the transcriptional regulatory activity of this protein, thereby abolishing the virus’s ability to induce lymphomas [4]. Sato et al. (2025) demonstrated that engineering these two substitutions into the backbone of the very virulent RB-1B strain (rRB-1B_Meq71/77) completely abrogated virulence, with infected chickens developing neither clinical signs nor lymphomas, and flow cytometry revealing no expansion of infected cells [4]. This finding provides definitive molecular evidence that the Meq polymorphisms are sufficient to explain the attenuation phenotype of CVI988.

Beyond Meq, CVI988 also exhibits a distinctive genomic architecture that includes a 178-base pair insertion within the meq open reading frame, giving rise to a longer transcript termed L-meq [13, 24]. This insertion encodes an altered transactivation domain that further compromises the oncogenic potential of the virus. Importantly, the L-meq isoform is not unique to CVI988; it can be detected transiently during latent infection with virulent strains, suggesting that the virus population undergoes dynamic shifts between meq and L-meq subpopulations during the course of infection [24]. However, in CVI988, the L-meq isoform predominates throughout the infection cycle, contributing to its stable non-oncogenic phenotype [13, 24]. The differential splicing landscape of CVI988 compared to virulent strains such as RB-1B is another distinguishing feature; despite sharing >99% sequence identity, these strains exhibit profoundly different transcriptomic profiles, with numerous splicing isoforms being strain-specific [14]. This observation underscores the complexity of MDV gene regulation and suggests that post-transcriptional mechanisms play a substantial role in determining virulence and vaccine efficacy.

Serotype 2 Vaccine Strains: SB-1 and the Bivalent Synergy

Serotype 2 (GaHV-3) viruses are naturally non-oncogenic and have been exploited as vaccines, with strain SB-1 being the most prominent example [1]. SB-1 was isolated from apparently healthy chickens and, when used alone, provides moderate protection against MDV challenge. However, its true value emerges when combined with HVT in a bivalent formulation (HVT/SB-1), which demonstrates synergistic protective efficacy that exceeds the sum of the individual components [1]. The mechanistic basis for this synergism has been elucidated through transcriptional profiling studies. Neerukonda et al. (2019) demonstrated that ex vivo infection of splenocytes with HVT, SB-1, or the bivalent combination induced interferon (IFN) and IFN-stimulated gene expression, with additive effects observed for key innate immune genes including TLR3, IFN-γ, OASL, Mx1, NOS2A, and IL-1β [1]. In ovo vaccination with HVT/SB-1 accelerated immune maturation, promoting the migration of T cells and natural killer cells into the spleen, and induced a coordinated upregulation of IL-12p40 with concomitant downregulation of suppressors of cytokine signaling 1 and 3 (SOCS1 and SOCS3), indicative of classical M1 macrophage and Th1 polarization [1]. This immunological priming likely underpins the enhanced protection observed with bivalent vaccination.

Serotype 3 Vaccine Strains: Herpesvirus of Turkeys (HVT)

HVT (MeHV-1) is a naturally occurring virus of turkeys that is completely apathogenic in chickens yet shares sufficient antigenic cross-reactivity with MDV to confer protective immunity [1, 8, 17]. Strain FC-126 is the prototypical HVT vaccine strain and has been used globally for decades, either alone or in combination with serotype 1 or serotype 2 strains [19]. HVT is particularly valued for its safety profile, its ability to be administered in ovo at embryonic day 18, and its utility as a vector platform for recombinant vaccines expressing immunogenic proteins from other avian pathogens [17, 23]. The HVT genome has been engineered to express the fusion (F) protein of Newcastle disease virus (NDV) and the VP2 protein of infectious bursal disease virus (IBDV), yielding the trivalent HVT-ND-IBD vaccine, which simultaneously protects against three major viral diseases [23]. Additionally, HVT vectors carrying computationally optimized broadly reactive antigen (COBRA) hemagglutinin inserts from H5 high pathogenicity avian influenza (HPAI) viruses have demonstrated broad cross-protection against antigenically diverse H5Nx strains, highlighting the versatility of this platform [17]. The World Health Organization (WHO) and WOAH have recognized the importance of such vectored vaccines in integrated poultry disease control programs, particularly in regions where HPAI is endemic.

Recombinant and Genetically Engineered Vaccine Strains

The limitations of conventional live vaccines, namely, their inability to provide sterilizing immunity and their potential to drive virulence evolution through imperfect vaccination, have spurred the development of next-generation vaccine candidates [2, 15, 20]. One prominent strategy involves the deletion of the meq oncogene from virulent MDV backbones, generating attenuated viruses that retain immunogenicity. The rMd5-BACΔMeq vaccine, derived from the very virulent Md5 strain, protects against vv+MDV challenge but induces significant lymphoid organ atrophy, particularly of the bursa and thymus, in maternal antibody-negative chickens [5, 9, 18]. To mitigate this adverse effect, Conrad et al. (2021) further deleted the viral thymidine kinase (tk) gene from the ΔMeq backbone, yielding rMd5B40/Δmeq/Δtk, which spared chickens from lymphoid atrophy but was less protective than CVI988 [18]. An alternative approach deleted both meq and vIL-8 from a vv+MDV strain (686BAC-ΔMeqΔvIL8), producing a vaccine that conferred protection comparable to CVI988 while significantly reducing lymphoid organ atrophy relative to the single meq deletion mutant [9].

Another innovative strategy involves the insertion of the long terminal repeat (LTR) of reticuloendotheliosis virus (REV) into the CVI988 genome, generating a recombinant virus (rMDV) with enhanced replication kinetics in vitro and superior protection against vvMDV challenge at low doses [22]. This approach exploits the natural propensity of MDV to integrate REV-LTR sequences, which have been detected in numerous field isolates from vaccinated flocks, suggesting that such recombinants may arise spontaneously in nature [22]. The safety profile of rMDV was confirmed through serial passage in chickens, with no evidence of reversion to virulence or genomic instability [22].

Emerging Recombinants and the Evolution of Vaccine Resistance

A critical concern in MDV vaccinology is the emergence of natural recombinants between vaccine strains and virulent field strains, a phenomenon directly attributable to the non-sterilizing nature of current vaccines [2]. Zhang et al. (2022) isolated six recombinant MDV strains from commercial flocks in China that contained the CVI988 vaccine skeleton with partial replacement of the unique short (Us) region from virulent strains [2]. These recombinants, while not lethal, exhibited enhanced replication capability, reaching viral loads comparable to the very virulent LHC2 strain, and induced notable splenomegaly with mild thymic and bursal atrophy [2]. This finding provides direct evidence that live vaccines can serve as genetic donors for recombination, generating novel viruses with intermediate virulence that may complicate disease diagnosis and control. The emergence of such recombinants is particularly concerning in regions where multiple vaccine strains are used concurrently, as the co-circulation of HVT, SB-1, and CVI988 in the same flocks creates opportunities for inter-serotypic recombination [2, 6].

The selective pressure exerted by vaccination has also driven the evolution of field strains with increased resistance to vaccine-induced immunity. Sun et al. (2017) characterized the Chinese field strain BS/15, which, despite exhibiting virulence comparable to Md5, demonstrated remarkable vaccine resistance: the protective indices of CVI988 and 814 against BS/15 were only 33.3 and 66.7, respectively, compared to 92.9 and 100 against Md5 [12]. Similarly, the strain DH/18, which caused weaker pathogenic damage than AH/1807, was paradoxically more capable of breaking through CVI988 vaccine protection, with an immune protection index of only 61.1 [3]. These observations indicate that vaccine resistance and virulence are not necessarily correlated; strains may evolve to evade vaccinal immunity without concomitant increases in pathogenicity, a phenomenon that complicates risk assessment and surveillance efforts [3, 12].

Taxonomic and Diagnostic Implications

The accurate taxonomic classification of MDV vaccine strains is essential for both epidemiological surveillance and vaccine quality control. Molecular diagnostic tools have been developed to differentiate vaccine strains from field isolates, leveraging polymorphisms in the meq, pp38, and vIL-8 genes [7, 10, 11, 21]. A quadruplex real-time PCR assay targeting HVT, CVI988, and virulent MDV-1 simultaneously has been validated for monitoring vaccine replication and detecting breakthrough infections in feather pulp samples [10]. The CRISPR/Cas14a-based detection system, combined with recombinase polymerase amplification (RPA), offers a portable, visual readout method capable of distinguishing epidemic MDV-1 strains from vaccine strains with a detection limit of 24.6 copies/μL, making it suitable for field deployment in resource-limited settings [11]. These diagnostic advances are critical for WOAH-compliant surveillance programs and for evaluating the efficacy of vaccination campaigns in real time.

The genomic heterogeneity of vaccine strains themselves poses additional taxonomic challenges. Ortigas-Vásquez et al. (2023) demonstrated that consensus genomes of CVI988 obtained from different sources varied in as many as 236 positions involving 13 open reading frames, with 19 single nucleotide polymorphisms (SNPs) in the unique regions of one BAC-derived genome that were absent in two other independently sequenced CVI988 stocks [16]. This intrastrain variation, arising from the mixed viral populations inherent in live vaccines, underscores the need for multiple consensus genomes per strain to maximize the accuracy of inter-strain genomic comparisons and to ensure the consistency of vaccine seed stocks [16]. The implications for regulatory oversight are substantial: vaccine manufacturers must implement rigorous quality control measures to monitor the genetic stability of vaccine strains during production and passage, as even minor sequence variations could potentially alter immunogenicity or safety profiles.

Molecular Pathogenesis of Marek's Disease Virus and Vaccine-Induced Protection

Marek’s disease virus (MDV), classified as Mardivirus gallidalpha2 within the Alphaherpesvirinae subfamily, is the etiological agent of Marek’s disease (MD), a highly contagious lymphoproliferative disorder of chickens that remains one of the most economically significant viral pathogens affecting global poultry production. The molecular pathogenesis of MDV is a multifaceted process governed by a complex interplay between viral gene products and host cellular machinery, culminating in T-cell lymphoma formation, profound immunosuppression, and neurological dysfunction. Critically, the widespread deployment of live-attenuated vaccines, while effectively preventing clinical disease and tumor formation, does not confer sterilizing immunity. This fundamental limitation has created a unique evolutionary landscape where vaccinal pressure drives the relentless emergence of increasingly virulent field strains, a phenomenon that has necessitated successive generations of more potent vaccines and underscores the urgent need to understand the precise molecular mechanisms underlying both pathogenesis and vaccine-induced protection.

The Molecular Architecture of MDV Virulence and Oncogenesis

The capacity of MDV to induce rapid-onset T-cell lymphomas is orchestrated primarily by the viral oncoprotein Meq (Marek’s EcoRI-Q-encoded protein), a functional homologue of the mammalian Jun/Fos family of basic leucine zipper (bZIP) transcription factors. The meq gene, encoded within the repeat regions flanking the unique long (UL) region of the MDV genome, is indispensable for transformation and tumor formation [15, 27]. Meq exerts its oncogenic effects through a bipartite domain structure: an N-terminal bZIP domain mediates DNA binding and dimerization, while the C-terminal transactivation domain governs transcriptional regulatory activity. Elegant gain- and loss-of-function studies have delineated the discrete contributions of these domains. Chimeric virus experiments swapping the DNA-binding and transcriptional regulatory domains between the very virulent Md5 strain and the attenuated CVI988 vaccine strain revealed that the DNA-binding domain is essential for transformation and tumor incidence, whereas the transcriptional regulatory domain dictates tumor distribution and size [27]. Specifically, recombinant viruses bearing the CVI988 transcriptional regulatory domain within an Md5 backbone induced 100% mortality and generated very large visceral tumors, while those with the CVI988 DNA-binding domain exhibited drastically reduced tumorigenicity, with only 37% mortality and rare, small visceral tumors [27]. These findings establish that the molecular determinants of attenuation reside, at least in part, within the Meq DNA-binding interface.

Virulent field strains universally harbor a 339-amino-acid Meq protein, while attenuated strains, most notably CVI988, carry a 180-base-pair insertion within the meq open reading frame, generating a longer variant designated L-meq [13, 24]. This insertion disrupts the transcriptional regulatory capacity of the oncoprotein, providing a direct molecular correlate of attenuation. Critically, polymorphisms within the Meq protein, particularly at positions 71 (A71S) and 77 (K77E), which are characteristic of CVI988, are sufficient to abolish MDV virulence. Recombinant viruses based on the very virulent RB-1B strain engineered to harbor these two substitutions failed to induce clinical signs or lymphomas in infected chickens, and histopathological analysis confirmed the complete absence of MD-associated lesions [4]. Mechanistically, these substitutions markedly impair the transcriptional regulatory activity of Meq, as demonstrated by reporter assays, and are associated with a striking expansion of CD8+ T cells and γδ T cells during early infection, suggesting that the loss of Meq-mediated immune evasion permits robust host antiviral responses that abort tumorigenesis [4].

Beyond Meq, several other viral genes contribute to the pathogenic phenotype. The viral interleukin-8 (vIL-8) gene, a CXC chemokine homologue, plays a critical role in chemoattraction and viral dissemination. Deletion of vIL-8 from the viral genome abrogates the lymphoid organ atrophy characteristic of MDV infection, while deletion of meq alone, although attenuating oncogenicity, paradoxically retains the capacity to induce significant lymphoid atrophy [9]. This finding highlights the functional segregation of pathogenic determinants: meq governs transformation and tumor formation, while vIL-8 mediates the early immunosuppressive phase of infection. The double deletion mutant (ΔMeqΔvIL8) not only eliminates both oncogenicity and lymphoid atrophy but also confers protection comparable to the commercial CVI988 vaccine against challenge with very virulent plus (vv+) MDV strains, representing a promising next-generation vaccine candidate [9].

Virulence Determinants and the Molecular Basis of Pathotype Differentiation

The continuous evolution of MDV towards higher virulence has been accompanied by the accumulation of specific genetic markers that distinguish pathotypes. Comparative genomic analyses of 70 MDV strains with known virulence phenotypes have identified numerous genetic variants associated with virulence, distributed across multiple loci, confirming that MDV virulence is a complex, polygenic trait [31]. High virulence isolates from the same farms persisted over years despite eradication efforts, underscoring the challenge of controlling genetically entrenched viral populations [31]. Among the most informative markers are mutations in the meq gene. Field strains from Nigeria, for example, have been found to harbor mutations characteristic of both European and US high virulence lineages, including an RB1B-like lineage co-circulating with a European Polen5-like lineage, as well as recombinants combining mutations from both clades [26]. This genetic admixture suggests that international trade and movement of poultry have facilitated the mixing of previously geographically distinct virulence genotypes, potentially accelerating the emergence of pathotypes with unprecedented pathogenic potential, including a hypothetical "very virulent plus plus" (vv++) pathotype [26].

Similarly, MDV field strains circulating in Tanzania exhibit high sequence similarity with strains from Egypt, Nigeria, Israel, and China, and contain amino acid substitutions in Meq, pp38, and vIL-8 that are associated with increased virulence [6]. In China, the isolation of highly pathogenic strains such as SS1901, which carries mutations at K77E, D80Y, V115A, T139A, P176R, and P217A in Meq, along with additional novel mutations A88T and Q93R, demonstrates the ongoing diversification of virulence determinants [29]. This particular isolate caused 100% mortality and 80% tumor incidence in specific-pathogen-free (SPF) chickens and exhibited resistance to vaccine protection, with HVT, 814, and CVI988 vaccines providing only 46.7%, 80%, and 73.3% protection, respectively, while the combination of CVI988 and HVT achieved 86.7% protection [29]. The molecular divergence observed in these field isolates underscores the capacity of MDV to continuously refine its pathogenic arsenal under vaccinal pressure.

The Host Antiviral Response: From Innate Sensing to Adaptive Immunity

The outcome of MDV infection is profoundly influenced by the host's capacity to mount an effective antiviral response, which is shaped by both genetic determinants and prior vaccination. The innate immune system serves as the first line of defense, with pattern recognition receptors such as Toll-like receptors (TLRs) playing a pivotal role in virus sensing. Transcriptional profiling of splenocytes infected ex vivo with vaccine strains (HVT, SB1, or HVT/SB1) revealed that vaccination induces robust expression of type I interferon (IFN) and interferon-stimulated genes (ISGs), including OASL, Mx1, and NOS2A, with relatively modest proinflammatory cytokine induction [1]. This pattern of innate activation is consistent with a protective antiviral state rather than a destructive inflammatory response. Moreover, the bivalent HVT/SB1 vaccine demonstrated additive or synergistic effects on the expression of TLR3, IFN-γ, OASL, Mx1, NOS2A, and IL-1β, providing a molecular basis for the enhanced protection conferred by bivalent vaccination compared to either component alone [1].

The early innate response is critically dependent on the induction of type I interferons. Infection with virulent MDV strains, such as the vaccine-resistant DH/18 isolate, causes a profound suppression of IFN-β and IFN-γ expression, and this immunosuppression persists even in vaccinated birds, enabling the virus to replicate to high titers and break through vaccine protection [3]. In contrast, less virulent strains induce a more robust interferon response that correlates with better vaccine efficacy. The importance of the interferon axis is further emphasized by studies demonstrating that co-administration of probiotic lactobacilli with HVT vaccine enhances the expression of IFN-α in the spleen following MDV challenge, reduces the number of CD4+CD25+ regulatory T cells, and decreases tumor incidence by half compared to HVT alone [8]. This immunomodulatory effect likely operates through the enhancement of antigen presentation, as evidenced by increased major histocompatibility complex (MHC) class II expression on macrophages and B cells [8].

Adaptive immunity, particularly the cytotoxic T lymphocyte (CTL) response, is essential for controlling MDV infection and preventing tumor formation. The magnitude and specificity of the T cell response are heavily influenced by the host's MHC haplotype. Chickens with the MD-resistant B21 haplotype (line N) mount significantly higher frequencies of IFN-γ-producing T cells specific for the immunodominant antigens pp38 and Meq compared to MD-susceptible B19 haplotype (line P2a) chickens [32]. Vaccination of resistant chickens boosts both pp38- and Meq-specific effector T cell responses, whereas vaccination of susceptible chickens fails to induce Meq-specific effector T cells, revealing a critical deficiency in the ability to mount a comprehensive antiviral response [32]. The structural basis of CTL epitope presentation has been elucidated through X-ray crystallography of chicken MHC class I (pBF2*1501) molecules complexed with MDV-derived peptides. The antigen-binding groove accommodates both 8-mer and 9-mer peptides, with the 9-mer displaying a characteristic "M-type" epitope morphology that facilitates robust T cell activation [34]. Immunization with dominant CTL epitopes, delivered with a protein adjuvant (HSP108-N333), achieved a protective index of 33% and reduced mortality to 20% upon challenge, demonstrating that even a single epitope can induce potent antitumor T cell immunity when properly presented [34].

Vaccine-Induced Immunological Memory and Systemic Protection

The mechanisms by which vaccines confer long-term protection against MDV tumorigenesis, despite failing to prevent viral superinfection, have remained enigmatic. Recent evidence points to a central role for serum exosomes in mediating systemic vaccine-induced immunity. Exosomes isolated from the serum of CVI988-vaccinated and protected chickens (VEX) contain a vastly different molecular cargo compared to exosomes from unvaccinated, lymphoma-bearing chickens (TEX) [33]. VEX are enriched in tumor suppressor microRNAs (miRNAs), whereas TEX are dominated by oncomiRs, including those originating from both cellular (miR-106a-363) and MDV-encoded miRNA clusters [33]. Most strikingly, VEX contain mRNAs mapping to the entire MDV genome, while TEX contain only mRNAs mapping to the internal repeat long (IRL) and terminal repeat long (TRL) regions [33]. This observation suggests that vaccine-derived exosomes continuously deliver viral antigens to antigen-presenting cells throughout the body, maintaining a state of systemic immune surveillance. The transfer of these exosomal viral mRNAs to dendritic cells or macrophages could sustain long-term T cell memory by providing a persistent source of antigen, a mechanism that would explain why vaccinated birds remain protected for extended periods despite the presence of replicating field virus.

Further insight into the immunological correlates of vaccine protection has been gained through transcriptional profiling of lymphoid tissues following in ovo vaccination. Administration of a bivalent MDV mRNA vaccine encoding glycoprotein B (gB) and phosphoprotein 38 (pp38) induces rapid, tissue-specific transcriptional responses [28]. In the spleen, early activation of caudal-type homeobox 1 (CDX1) and signal transducer and activator of transcription 1 (STAT1) is accompanied by the induction of interferon-stimulated antiviral genes, including MX1, OASL, and IFIT5 [28]. In contrast, the bursa of Fabricius exhibits persistent modulation of genes involved in metabolic and apoptotic remodeling, such as colipase (CLPS), chymotrypsinogen B1 (CTRB1), and deoxyribonuclease I (DNASE1) [28]. This organ-specific divergence in transcriptional programming highlights the need for vaccines to engage both systemic (splenic) and mucosal (bursal) immune compartments to achieve comprehensive protection.

The Dark Side of Vaccination: Immune Pressure and the Evolution of Vaccine Resistance

The reliance on live, non-sterilizing vaccines has inadvertently created a powerful selective pressure that drives MDV evolution towards increased virulence and vaccine resistance. This phenomenon is most starkly illustrated by the isolation of natural recombinant MDV strains arising from genetic exchange between vaccine and virulent strains. In China, six natural recombinant strains were isolated from vaccinated commercial flocks, all of which resulted from recombination between the CVI988 vaccine strain skeleton and the unique short (US) region of virulent field strains [2]. These recombinants, exemplified by HC/0803 and DH/1307, exhibited mild virulence with temporal immune organ damage but replicated to levels comparable to the highly virulent LHC2 strain, reaching approximately 10⁷ viral copies per million host cells at 17 days post-challenge [2]. The emergence of such recombinants provides direct evidence that live vaccines can act as genetic donors for genomic recombination, a safety concern that has significant implications for the design and deployment of future vaccines.

The capacity of field strains to overcome vaccine immunity is not solely a function of increased replication; it also involves sophisticated immune evasion mechanisms. The Chinese variant strain BS/15, isolated from a CVI988-vaccinated flock exhibiting severe disease, demonstrated a striking divergence between its virulence and vaccine resistance [12]. Although BS/15 and the reference strain Md5 caused similar mortality rates (85.7% versus 80.0%) in unvaccinated chickens, BS/15 induced a higher tumor rate (64.3% versus 40.0%) yet exhibited prolonged survival and diminished immune defects compared to Md5 [12]. Critically, the protective indices of CVI988 and 814 vaccines against BS/15 were only 33.3 and 66.7, respectively, compared to 92.9 and 100 against Md5, indicating that BS/15 possesses specific adaptations that allow it to evade the vaccine-induced immune response without necessarily being more virulent in naïve hosts [12]. This uncoupling of virulence from vaccine resistance suggests that field strains can acquire mutations that specifically target the components of immunity most effectively stimulated by vaccination, a finding that complicates the prediction of vaccine efficacy based solely on pathotype classification.

The suppression of host interferon responses is a key mechanism by which virulent strains achieve vaccine resistance. The DH/18 strain, which exhibited weaker pathogenic damage but could break through CVI988 vaccine protection, caused stronger immunosuppression than the more pathogenic AH/1807 strain, as evidenced by a more profound decline in IFN-β and IFN-γ expression [3]. This immunosuppression persisted even after vaccination, allowing DH/18 to replicate to higher titers and ultimately overwhelm vaccine immunity [3]. These observations underscore the need for vaccines that not only induce strong effector responses but also counteract the immunosuppressive strategies of emerging field strains.

The Interplay of Co-infections and Environmental Modulators

The complexity of MDV pathogenesis is further amplified by co-infections with other avian pathogens. Co-infection with MDV and reticuloendotheliosis virus (REV), a common occurrence in commercial flocks, results in synergistic pathogenicity, with mortality increasing from 76.7% to 96.7% and tumor rates increasing from 53.3% to 80.0% compared to MDV infection alone [30]. This synergy is accompanied by increased expression of meq, pp38, vIL-8, and ICP4 in the spleen at certain time points, suggesting that REV co-infection enhances the transcriptional activity of MDV oncogenes [30]. The impact on vaccine efficacy is profound: the protective index of CVI988 decreased from 80.0 to 47.7, and that of 814 decreased from 90.0 to 76.7, in co-infected birds [30]. These findings highlight the vulnerability of MD vaccination programs to the broader pathogen landscape within poultry flocks.

Environmental factors also modulate the host-virus interaction. The administration of Toll-like receptor ligands encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles at embryonic day 18, followed by post-hatch boosting, significantly reduced tumor incidence by 60% (CpG) and 42.8% (LPS) at 21 days post-infection [35]. This protection correlated with the expression of proinflammatory cytokines IL-1β and IL-18, suggesting that early activation of innate immunity can establish an antiviral state that curbs tumor development [35]. Similarly, plant-derived compounds with antiviral activity, such as curcumin from Curcuma longa, have demonstrated plaque reduction percentages of 80% against HVT and 66% against Rispens at a 1:8 virus dilution, indicating potential as adjunctive therapies [25]. These approaches, while not substitutes for vaccination, offer avenues for reducing viral load and enhancing the efficacy of existing vaccines.

Differential Efficacy of Vaccine Platforms: Molecular Underpinnings

Not all vaccines are equivalent in their capacity to induce protective immunity, and the molecular basis for these differences is increasingly well understood. The three major vaccine platforms, herpesvirus of turkeys (HVT, serotype 3), SB1 (serotype 2), and CVI988 (serotype 1), engage the host immune system in distinct ways. Ex vivo infection of splenocytes with HVT, SB1, or HVT/SB1 revealed that the bivalent vaccine induces a more coordinated and robust activation of innate and adaptive immune pathways compared to either component alone [1]. Specifically, HVT/SB1 vaccination resulted in a coordinated induction of IL-12p40, a key cytokine driving T-helper 1 (Th1) polarization, along with downregulation of suppressors of cytokine signaling (SOCS) 1 and 3 [1]. This pattern is indicative of classical M1 macrophage activation and Th1 skewing, which is critical for effective antiviral CTL responses. Furthermore, HVT/SB1 vaccination appeared to hasten immune maturation, with expression patterns suggesting accelerated migration of T cells and natural killer (NK) cells into the spleen [1].

The quality of the T cell memory response also differs between vaccine platforms. Flow cytometric analysis of chickens vaccinated with CVI988 and challenged with virulent MDV revealed a significant and specific increase in the CD8α(high) TCR1(+) cell population in the spleen at 21 days post-infection, a population that was not expanded in unvaccinated challenged birds [36]. This population, characterized by bright CD8α expression, represents a relatively rare subset but is specifically

Epidemiology of Marek's Disease and Global Vaccine Strain Usage

Marek’s disease (MD) exemplifies one of the most complex epidemiological challenges in modern veterinary virology, representing a paradigm of vaccine-driven pathogen evolution coupled with the constant emergence of more virulent field strains. The etiological agent, Marek’s disease virus (MDV; Mardivirus gallidalpha2), is a highly cell-associated alphaherpesvirus that induces a rapid-onset T-cell lymphoproliferative syndrome in chickens, leading to paralysis, immunosuppression, and visceral lymphoma formation [1, 15]. The disease is recognized by the World Organisation for Animal Health (WOAH) as a significant constraint on global poultry production, and its control remains a cornerstone of commercial poultry health management worldwide. Despite the universal application of live-attenuated and non-pathogenic vaccines for over five decades, MDV continues to circulate unabated in vaccinated flocks, imposing a perpetual economic burden and driving a relentless evolutionary arms race between the virus and its immunological countermeasures.

The Global Burden and Evolutionary Trajectory of MDV Pathotypes

The epidemiological landscape of MD has been defined by a stepwise escalation in virulence, a phenomenon directly linked to the deployment of successive generations of imperfect, non-sterilizing vaccines. Initial field isolates from the 1960s, classified as mild (m) strains, were effectively controlled by the first-generation vaccine, the herpesvirus of turkeys (HVT; serotype 3). However, the emergence of virulent (v) and very virulent (vv) pathotypes in the 1970s and 1980s necessitated the introduction of bivalent vaccines (HVT plus the naturally apathogenic serotype 2 strain SB-1) and the highly protective serotype 1 attenuated vaccine, CVI988/Rispens [1, 15]. Contemporary epidemiology now documents the widespread circulation of very virulent plus (vv+) strains across multiple continents, including North America, Europe, and Asia, with recent reports suggesting the evolution of a putative very virulent plus plus (vv++) pathotype [15, 26]. This escalation is not merely a theoretical concern; it manifests as vaccine breakthrough outbreaks, increased lymphoma incidence, and profound immunosuppression in affected flocks.

Surveillance studies have confirmed the global pervasiveness of highly virulent MDV. In China, a major epicenter of MDV evolution, molecular characterization of field isolates has repeatedly revealed strains that not only overcome CVI988-induced immunity but also harbor unique mutations in the major oncogene meq. For instance, the SS1901 strain, isolated from a CVI988-vaccinated farm in southern China, caused 100% mortality and 80% tumor incidence in specific-pathogen-free (SPF) chickens, and exhibited a high degree of vaccine resistance, with HVT, 814, and CVI988 providing only 46.7%, 80%, and 73.3% protection, respectively [29]. Similarly, the LZ1309 strain, isolated from a flock vaccinated with both HVT and CVI988, induced 100% morbidity and 90% mortality, with the bivalent vaccine achieving a protective index of only 90% [40]. These findings are mirrored across the continent, with studies from Egypt and Turkey identifying field strains that cluster phylogenetically with highly virulent European and Asian isolates, sharing critical amino acid substitutions in Meq (such as P217A, R101K, and E263D) that are absent in the vaccine strains [37, 39]. The epidemiological significance of these mutations is profound; they are associated with enhanced transcriptional activation of genes involved in cell proliferation and immune evasion, directly contributing to the failure of vaccinal immunity.

Global Vaccine Strain Usage Patterns and the Imperfect Vaccine Dilemma

The global vaccination strategy against MD relies predominantly on three core vaccine types: HVT (serotype 3), SB-1 (serotype 2), and CVI988/Rispens (serotype 1). These are used either singly or in various bivalent and trivalent combinations, with the specific regimen often dictated by the anticipated challenge pressure, the longevity of the bird (broiler versus layer or breeder), and local epidemiological conditions. In commercial broiler production, HVT and its recombinant derivatives (rHVT) are favored for in ovo administration due to their safety, early replication, and ability to serve as vectors for protective antigens from other avian pathogens, such as Newcastle disease virus and infectious bursal disease virus [23]. In contrast, high-value layers and breeders, which face a longer exposure window, are routinely vaccinated with the bivalent HVT/SB-1 or a combination of HVT and CVI988 to achieve broader and more durable immunity [1].

The efficacy of these vaccines, however, is inherently compromised by their inability to induce sterile immunity. CVI988, while exceptionally effective at preventing clinical disease and lymphoma formation, does not block MDV infection, replication, or horizontal transmission [15]. This creates an epidemiological niche in which vaccinated birds become reservoirs for the continuous amplification and shedding of field viruses. The relentless replication of these field strains in the presence of vaccine-induced immune pressure is the primary driver of virulence evolution. This phenomenon is well-illustrated by the emergence of natural recombinants between vaccine and virulent strains. In China, researchers have isolated six distinct natural recombinant MDVs that arose through recombination between the CVI988 vaccine strain skeleton and the unique short (Us) region of virulent field strains. These recombinants, such as HC/0803 and DH/1307, exhibited a mild virulence phenotype with temporal immune organ damage and significantly higher replication capacity than the CVI988 parent, confirming that live vaccines can act as genetic donors for genomic recombination, thereby increasing genetic diversity and diagnostic complexity [2]. This finding underscores a fundamental safety concern: the widespread use of live vaccines in high-density poultry populations creates a dynamic genetic environment where attenuated vaccine genomes can recombine with circulating virulent viruses, potentially generating novel pathogens with unpredictable pathogenic properties.

Regional Epidemiological Patterns and the Molecular Signatures of Vaccine Resistance

Epidemiological surveillance across diverse geographic regions has revealed distinct patterns of MDV circulation and vaccine strain usage, shaped by local husbandry practices, biosecurity levels, and vaccination history. In Africa, where poultry production is rapidly intensifying, studies have documented the widespread circulation of MDV with a prevalence as high as 18% in Tanzania [6]. Phylogenetic analyses of the meq, pp38, and vIL-8 genes from Tanzanian isolates revealed high sequence similarity with strains from Egypt, Nigeria, Israel, and China, indicating a global dissemination of virulent lineages. Critically, these African isolates harbored amino acid substitutions in Meq that are well-established markers of increased virulence, mirroring those found in European and US vv+ strains [6]. In Nigeria, the situation is even more complex; meq gene sequencing from outbreak farms revealed a co-circulation of an RB-1B-like lineage (representative of US high virulence) and a European Polen5-like lineage, along with recombinant strains combining mutations from both. This intercontinental admixture of genetic backgrounds suggests that the selection pressure imposed by specific vaccination strategies directly shapes the evolution of Meq. The authors of this study posited that this genetic convergence is a harbinger of the next evolutionary step, the emergence of a vv++ pathotype [26].

The molecular basis for vaccine resistance is increasingly understood to reside within the meq gene, the principal oncogene of MDV. Polymorphisms in the basic region and leucine zipper (bZIP) domain of Meq are critical determinants of both virulence and the ability to overcome vaccine-induced immunity. The CVI988 vaccine strain itself harbors unique polymorphisms at amino acid positions 71 (A71S) and 77 (K77E) in the basic region of Meq. Recombinant virus studies have demonstrated that introducing these two specific substitutions into the very virulent RB-1B backbone is sufficient to completely abolish virulence, resulting in no clinical signs, no lymphoma formation, and the induction of a robust protective CD8+ T-cell response [4]. Conversely, field isolates that have evolved to escape vaccine pressure frequently exhibit reversions or alternative mutations at these critical positions. The SS1901 strain, for example, carries a K77E substitution, which is a direct reversion to the attenuated CVI988 sequence at that position, suggesting a complex interplay between attenuation and reversion in the field [29]. Furthermore, the swapping of the DNA-binding domain and transcriptional regulatory domain of Meq between the very virulent Md5 strain and CVI988 has revealed that the DNA-binding domain is the primary driver of tumor incidence, while the transcriptional regulatory domain influences tumor distribution and size [27]. These findings collectively demonstrate that the epidemiology of MDV vaccine resistance is fundamentally a story of molecular adaptation at the level of the Meq oncoprotein, where subtle amino acid changes can profoundly alter pathogenicity and the capacity to evade vaccine-primed immune responses.

The Role of Recombination and Genomic Plasticity in Sustaining Epidemics

The genomic plasticity of MDV, particularly its capacity for recombination, is a major epidemiological force that sustains the pathogen in vaccinated populations. The co-administration of multiple vaccine strains (e.g., HVT and CVI988) creates opportunities for homologous recombination, not only between vaccine and field strains but also between different vaccine strains themselves. The emergence of natural recombinants carrying the CVI988 skeleton with virulence-associated Us region segments demonstrates that this is not a rare laboratory phenomenon but a recurrent event in commercial flocks [2]. Additionally, the integration of avian retrovirus long terminal repeats (LTRs) into the MDV genome, as seen with reticuloendotheliosis virus (REV) LTRs, can alter viral replication kinetics and pathogenicity. Recombinant viruses engineered with REV-LTR inserts replicate more rapidly in vitro and show altered safety profiles, suggesting that such natural insertions could influence field strain fitness and vaccine efficacy [22]. This genomic plasticity complicates disease diagnosis, as molecular assays must differentiate not only between serotypes but also between parental and recombinant forms. Advances in differential diagnostics, such as quadruplex real-time PCR assays that simultaneously detect HVT, CVI988, and virulent MDV-1, or CRISPR/Cas14a-based visual detection systems that specifically identify epidemic strains without cross-reactivity with vaccine strains, are essential tools for accurately monitoring the evolving epidemiological landscape [10, 11].

Vaccine Strain Replication Dynamics and Herd Immunity

The epidemiological outcome of a vaccination program is critically dependent on the replication dynamics of the vaccine strain within the host and its ability to establish a competitive ecological niche that limits field virus replication. Studies using quantitative PCR on feather pulp samples have demonstrated significant variation in the replication kinetics of different vaccine strains and their combinations. In Brazilian commercial flocks, the bivalent combination of CVI988 and HVT resulted in higher replication rates and greater vaccine coverage in feather tips compared to programs using rHVT vector vaccines [19]. Importantly, early challenge with oncogenic MDV generally does not interfere with the replication of CVI988, SB-1, or HVT in the feather pulp at seven days of age, indicating that the establishment of vaccine infection is robust even in the face of concurrent field virus exposure [38]. This has practical implications for monitoring vaccine take; feather pulp viral load at day 7 is a reliable indicator of vaccination success. Furthermore, the phenomenon of vaccine synergism, particularly the enhanced protection afforded by bivalent HVT/SB-1 compared to either vaccine alone, is linked to the induction of a more coordinated and robust innate and adaptive immune response. Transcriptional analyses have shown that bivalent vaccination induces an additive effect on the expression of interferon-stimulated genes (e.g., OASL, Mx1, NOS2A) and promotes a classical macrophage 1 (M1) and T-helper 1 (Th1) polarization, characterized by coordinated induction of IL-12p40 and downregulation of suppressors of cytokine signaling [1]. This mechanistic understanding highlights that vaccine epidemiology is not solely about strain selection; it is also about optimizing the immune microenvironment to outcompete the field virus.

Diagnostics for Marek's Disease Virus and Differentiation of Vaccine Strains

The accurate and timely diagnosis of Marek's disease virus (MDV) infection, coupled with the precise differentiation of vaccine strains from circulating field viruses, represents one of the most formidable challenges in avian virology and commercial poultry medicine. Unlike many viral pathogens where sterile immunity is achievable, MDV vaccines, including the gold-standard CVI988/Rispens, the turkey herpesvirus (HVT), and the naturally apathogenic serotype 2 strain SB-1, confer protection against clinical disease and tumor formation but do not prevent superinfection or viral replication [1, 2, 15]. This fundamental biological limitation creates a complex diagnostic landscape wherein vaccine viruses, field strains, and emerging natural recombinants co-circulate within vaccinated flocks, often simultaneously [2, 10, 37]. The diagnostic imperative, therefore, extends far beyond mere pathogen detection; it requires sophisticated molecular tools capable of discriminating between closely related viral genomes that may differ by as little as a single nucleotide polymorphism (SNP) or by the presence or absence of specific genetic insertions [7, 13, 24]. The economic and epidemiological consequences of misdiagnosis are profound. Failure to detect a vaccine breakthrough by an emerging virulent strain can lead to catastrophic lymphoma outbreaks, while misattributing vaccine virus replication as field strain infection may trigger unnecessary and costly regulatory interventions [10, 11, 41]. Consequently, the field of MDV diagnostics has evolved from traditional virological methods into a highly specialized discipline integrating real-time quantitative PCR (qPCR), multiplex PCR platforms, isothermal amplification technologies coupled with CRISPR-based detection, and deep sequencing approaches that interrogate the viral transcriptome for strain-specific signatures [7, 10, 11, 14, 21].

Molecular Platforms for Differential Detection: From qPCR to CRISPR-Based Diagnostics

The cornerstone of modern MDV diagnostics is the real-time quantitative PCR (qPCR) assay, which has been refined over the past decade to achieve remarkable specificity and sensitivity in differentiating vaccine strains from virulent field viruses. Baigent and colleagues developed, optimized, and rigorously validated a qPCR assay that exploits a single nucleotide polymorphism (SNP) within the pp38 gene to distinguish the CVI988 vaccine strain from virulent MDV serotype 1 field strains [7]. This assay demonstrated exceptional specificity with no false-positive results, accurate differential quantification over the biological range of virus levels encountered in clinical samples, and reproducible performance across feathers and blood, two sample types that are routinely collected for non-invasive monitoring in commercial flocks [7]. The mechanistic basis for this discrimination lies in the fact that CVI988, despite sharing >99% sequence identity with virulent strains such as RB-1B, harbors distinct genetic polymorphisms that have accumulated during its extensive passage history in cell culture [14, 16]. The pp38 SNP-based assay remains a gold-standard approach, but it is limited to distinguishing only CVI988 from other serotype 1 viruses and does not simultaneously differentiate the serotype 2 (SB-1) or serotype 3 (HVT) vaccine components that are frequently administered in bivalent or trivalent programs [1, 19].

To address this critical gap, Wu and colleagues developed a sophisticated quadruplex real-time PCR assay based on TaqMan probes that can simultaneously differentiate and accurately quantify HVT, CVI988, and virulent MDV serotype 1 strains in a single reaction [10]. The analytical performance of this assay is exceptional: the limit of detection (LOD) was determined to be 10 copies per reaction, with correlation coefficients exceeding 0.994 for all three target DNA molecules, and no cross-reactivity was observed with other avian pathogens including Newcastle disease virus, infectious bursal disease virus, or avian leukosis virus [10]. Intra-assay and inter-assay coefficients of variation (CVs) for cycle threshold (Ct) values were less than 3%, demonstrating excellent reproducibility [10]. This quadruplex assay was further validated by analyzing the replication kinetics of CVI988 and the very virulent strain Md5 in feather samples collected from 7 to 60 days post-infection, revealing that MD5 co-infection had no significant effect on the genomic load of CVI988 (p > 0.05), while vaccination with CVI988 significantly reduced the viral load of MD5 (p < 0.05) [10]. Importantly, when combined with conventional meq gene PCR, this method effectively identifies virulent MDV infections in immunized chickens, thereby confirming immunization status while simultaneously monitoring the circulation of pathogenic field strains [10]. Zhang and colleagues developed an alternative multiplex PCR (mPCR) method that targets the meq oncogene for serotype 1 differentiation and the gB genes of MDV-2 and MDV-3/HVT for serotype discrimination [21]. Using five specific primers in a single reaction, this mPCR produces amplicons of different sizes corresponding to the short meq (S-meq) and long meq (L-meq) of MDV-1 strains, as well as the gB of MDV-2 and HVT vaccine strains [21]. Analysis of 522 clinical samples from 30 poultry farms demonstrated that this method accurately detected and differentiated epidemic MDV-1 infections from vaccine strains, providing nearly 100% consistency with conventional PCR amplification of the meq gene for detecting clinical wild-type infections [21].

The most recent and technologically innovative addition to the diagnostic armamentarium is the integration of recombinase polymerase amplification (RPA) with CRISPR/Cas14a technology for visual detection of MDV [11]. Zhu and colleagues developed a portable isothermal detection system that operates at a constant temperature of 37°C and allows for either real-time fluorescence analysis or endpoint visual readout without the need for complex instrumentation [11]. The CRISPR/Cas14a system provides exquisite specificity, with no cross-reactivity observed against Newcastle disease virus, infectious bursal disease virus, MDV-1 vaccine strains (including CVI988), or HVT [11]. Using plasmid DNA standards, the detection limit was determined to be 24.6 copies/μL, and clinical evaluation using 24 field samples confirmed 100% agreement with reference methods [11]. The biological significance of this technology extends beyond its analytical performance; the ability to perform rapid, on-site visual detection without sophisticated laboratory infrastructure represents a transformative capability for field-based surveillance in regions where centralized diagnostic facilities are limited [11]. This is particularly relevant given the global circulation of MDV in diverse epidemiological contexts, including Africa, the Middle East, and Asia, where vaccine efficacy monitoring and early outbreak detection are critical for disease control [6, 29, 37, 39].

Genetic and Transcriptomic Signatures as Diagnostic Markers: The Meq Oncogene and Beyond

The meq oncogene (Marek’s EcoRI-Q-encoded protein) is the most extensively characterized genetic target for MDV strain differentiation, and for good reason: it is the principal oncogene of MDV, essential for tumor formation, and harbors genetic signatures that correlate with pathotype, vaccine attenuation, and regional evolution [4, 13, 15, 27]. The attenuated vaccine strain CVI988 carries a unique 178-180 base pair insertion within the meq open reading frame, resulting in a longer transcript known as L-meq, which is not present in fully virulent field strains such as Md5 or RB-1B [13, 24]. Lee and colleagues first demonstrated that PCR amplification of the meq gene from CVI988-infected cells yields both the native 1,062 bp band and an additional 1.2 kb band containing the 178 bp insertion, whereas oncogenic strains produce only the shorter amplicon [13]. Chang and colleagues further characterized the dynamics of meq and L-meq detection in chickens infected with various strains, revealing a fascinating population shift phenomenon: in chickens infected with very virulent strains like Md5 and RB-1B, the L-meq gene was detected only during the latent phase of infection (3 to 5 weeks post-inoculation), whereas in chickens infected with attenuated strains including CVI988, both L-meq and meq were detectable throughout the experimental period, with a larger amount of PCR product corresponding to L-meq [24]. These findings suggest that the MDV subpopulation displaying the L-meq gene is preferentially associated with latency, and the L-meq gene product may contribute to the maintenance of viral latency [24].

Beyond the L-meq insertion, specific amino acid polymorphisms within the basic region of Meq have been definitively linked to virulence attenuation. Sato and colleagues demonstrated that the substitutions A71S and K77E, which are hallmarks of the CVI988 strain, are sufficient to abolish MDV virulence when introduced into the backbone of the very virulent RB-1B strain [4]. Chickens infected with the recombinant virus rRB-1B_Meq71/77 developed neither clinical signs nor lymphomas, flow cytometry revealed no expansion of infected cells, and histopathological analysis confirmed the absence of MD-associated lesions [4]. Interestingly, these same polymorphisms have been observed in emerging field strains from China, India, and Italy, suggesting that the circulation of strains carrying vaccine-associated meq mutations may complicate diagnostic interpretation [29, 39]. Luo and colleagues reported that the highly pathogenic Chinese strain SS1901, isolated from a CVI988-vaccinated farm, harbored mutations including K77E alongside D80Y, V115A, T139A, P176R, and P217A, with additional mutations at A88T and Q93R that have been observed in MDV strains from southern China, India, and Italy [29]. This convergence of virulence-associated and vaccine-associated mutations in field isolates underscores the critical importance of comprehensive meq sequencing rather than reliance on single-marker diagnostic assays.

The complexity of MDV strain discrimination is further amplified by the phenomenon of pervasive differential splicing, which Sadigh and colleagues demonstrated can discriminate CVI988 from RB-1B even though these strains share >99% sequence identity [14]. Using RNA sequencing of chicken embryonic fibroblasts infected with either strain, they discovered a complex landscape of splicing events, most of which were previously uncharacterized and not annotated. Remarkably, a number of viral splicing isoforms were found to be strain-specific, and these differences were validated by developing a real-time PCR assay that detects RNA species present in CVI988-infected cells but absent in RB-1B-infected cells [14]. This transcriptomic approach represents a paradigm shift in MDV diagnostics, moving beyond genomic sequence comparison to functional RNA-based discrimination. The biological underpinnings of this phenomenon remain enigmatic, but the implications for diagnostic development are profound: strain-specific splicing can be exploited to design assays that are inherently more discriminatory than those based on DNA sequence alone [14].

The Challenge of Recombination and Vaccine-Virus Chimerism

Perhaps the most diagnostically challenging development in MDV epidemiology in recent years is the emergence of natural recombinant strains resulting from recombination between vaccine and virulent viruses. Zhang and colleagues isolated six natural recombinant MDV strains from infected chickens in commercial flocks in China and demonstrated through comprehensive genomic sequencing that these strains resulted from recombination between the CVI988 vaccine strain skeleton and the partial unique short region (US) of virulence strains [2]. Pathogenicity studies revealed that the recombinant strains HC/0803 and DH/1307, while not lethal, induced notable spleen enlargement, mild thymus and bursa atrophy, and viral genome loads peaking at approximately 10⁷ viral copies per million host cells, levels comparable to the very virulent strain LHC2 and significantly higher than CVI988 [2]. These findings provide direct evidence that live vaccines can act as genetic donors for genomic recombination, and they demonstrate that recombination promotes genetic diversity and increases the complexity of disease diagnosis, prevention, and control [2]. For diagnosticians, the emergence of recombinants means that standard SNP-based assays targeting CVI988-specific markers may yield false-positive results for virulent infection detection, or conversely, may fail to detect recombinant viruses that carry vaccine-derived sequences in diagnostic target regions [2, 10].

The implications of recombination for diagnostic strategy are further illustrated by the work of Patria and colleagues, who identified MDV field strains in Nigeria harboring meq mutations common to both European and US high-virulence strains [26]. Sequence analysis revealed an RB1B-like lineage co-circulating with a European Polen5-like lineage, as well as recombinants harboring combinations of these mutations, with mutations accumulating in both N-terminal and C-terminal domains of Meq [26]. Of particular concern is the possibility that vaccine strain SB-1, which is frequently used in bivalent combinations with HVT, may itself contribute to the recombination landscape [1, 19]. Ortigas-Vásquez and colleagues demonstrated that even within a single vaccine strain such as CVI988, consensus genomes can vary in as many as 236 positions involving 13 open reading frames (ORFs), and that ultra-deep sequencing reveals mixed viral populations within vaccine stocks [16]. This intrastrain variation complicates the interpretation of diagnostic results, as different passages or commercial preparations of the same vaccine strain may exhibit subtle genetic differences that affect detection by PCR-based assays [16].

Integration of Diagnostic Tools: Practical Algorithms for Field Application

The optimal diagnostic approach for MDV in commercial poultry operations integrates multiple complementary technologies within a decision-making algorithm that considers the specific epidemiological questions being addressed. For routine monitoring of vaccination efficacy, quantification of vaccine virus replication in feather pulp at 7–14 days post-vaccination by real-time PCR has become standard practice, with studies demonstrating that early challenge with oncogenic MDV does not interfere with vaccine DNA load in feather pulp at 7 days of age [19, 38]. Thiemann and colleagues conducted a retrospective analysis of data from nine animal experiments encompassing 46 treatment groups and found that CVI988, SB-1, and in most cases HVT replication in feather pulp was not affected by early infection with oncogenic MDV [38]. This finding validates the use of early feather pulp monitoring as a reliable indicator of vaccination take, independent of potential field virus exposure [38]. However, Muniz and colleagues demonstrated significant differences in replication rates between vaccination programs, with conventional bivalent CVI988/HVT vaccines showing higher replication rates and percentage of vaccine coverage than programs incorporating recombinant HVT vectored vaccines [19]. The mean log copy number of CVI988 varied significantly between programs at 14, 21, and 28 days of age, and the risk of being positive for CVI988 was 2.7 times higher in the conventional bivalent program compared to one of the recombinant HVT programs at 14 days [19].

For outbreak investigations and vaccine breakthrough assessment, a tiered diagnostic approach is recommended. Initial screening with a pan-MDV serotype 1 PCR targeting the meq gene can rapidly identify the presence of pathogenic field strains, and this approach has been successfully applied in multiple epidemiological contexts globally [6, 37, 39, 42]. Phylogenetic analysis of the meq gene from Tanzanian field strains revealed high sequence similarity with previously reported strains from Egypt, Nigeria, Israel, and China, with amino acid substitutions in meq associated with increased virulence [6]. Similarly, analysis of Egyptian field strains identified mutations R101K, P217A, and E263D present in all Egyptian viruses, as well as R176A and T180A mutations that contributed to the high virulence of these strains, while also revealing low amino acid identity with vaccine strains CVI988 and 3004 (up to 82.5%) [37]. For definitive strain differentiation in outbreak scenarios, sequencing of the entire meq gene, complemented by the pp38 SNP-based qPCR and the quadruplex TaqMan assay, provides the most comprehensive characterization [7, 10, 13, 29]. The RPA-CRISPR/Cas14a system offers a promising alternative for rapid field-based screening when laboratory access is limited, though its inability to detect vaccine strains means it is best suited for initial outbreak detection rather than comprehensive surveillance [11]. The multiplex PCR method developed by Zhang and colleagues provides an additional tool for simultaneous serotype identification and vaccine/field strain discrimination, particularly valuable in flocks receiving bivalent or trivalent vaccination programs [21]. As the global MDV landscape continues to evolve with the emergence of recombinant strains and vaccine-resistant pathotypes, the diagnostic toolkit must remain dynamic, integrating continuous genomic surveillance with refined molecular assays to ensure accurate differentiation and effective disease control [3, 12, 40].

Immune Responses Elicited by Monovalent and Bivalent Marek's Disease Vaccine Strains

The immunological mechanisms underlying protection conferred by Marek’s disease (MD) vaccines represent one of the most complex and nuanced areas of avian immunovirology. Unlike sterilizing vaccines that prevent infection entirely, MD vaccines, whether monovalent (e.g., herpesvirus of turkeys [HVT] or serotype 2 strain SB1) or bivalent (e.g., HVT/SB1 or HVT combined with CVI988/Rispens), operate by a paradigm of "imperfect" immunity. They effectively block the development of lymphomas and clinical disease but permit replication and shedding of virulent field strains. This fundamental characteristic has profound implications for immune response dynamics, vaccine synergism, and the evolutionary trajectory of Marek’s disease virus (MDV). The immune responses elicited by these vaccine strains are not merely quantitative differences in antibody titers or T-cell frequencies; they reflect distinct qualitative programming of innate and adaptive arms, tissue-specific kinetics, and molecular crosstalk that collectively determine whether a vaccinated bird resists tumor formation or succumbs to breakthrough infection.

Innate Immune Activation: Interferon Signaling and the Type I/Type II Axis

The earliest immune events following MD vaccination are dominated by the induction of type I interferons (IFN-α/β) and interferon-stimulated genes (ISGs), a response that differs markedly between monovalent and bivalent vaccine formulations. In ex vivo splenocyte infection models, HVT and SB1 individually induce IFN and ISG expression by 72 hours post-infection, but with a notable absence of robust proinflammatory cytokine induction [1]. This is a critical distinction from virulent MDV strains, which typically provoke a dysregulated and often detrimental inflammatory cascade. The bivalent combination HVT/SB1, however, produces an additive effect on the expression of key antiviral genes, including TLR3, IFN-γ, OASL, Mx1, NOS2A, and IL-1β, suggesting that the two vaccine components engage overlapping but synergistic innate pathways [1]. This additive gene expression profile implies that bivalent vaccination amplifies the magnitude of the innate antiviral state without tipping into pathological inflammation.

Transcriptional analyses of in ovo-vaccinated commercial broiler embryos reinforce this pattern. Administration of HVT/SB1 or a recombinant HVT-based bivalent combination (HVT-LT/SB1) accelerates immune maturation in the spleen, with expression patterns indicative of hastened migration of T cells and natural killer (NK) cells into this lymphoid organ [1]. The coordinated induction of IL-12p40 coupled with the downregulation of suppressors of cytokine signaling 1 and 3 (SOCS1 and SOCS3) is particularly significant, as this molecular signature points to classical macrophage 1 (M1) and T-helper 1 (Th1) polarization [1]. This suggests that bivalent vaccination actively shapes the early cytokine milieu toward a cell-mediated immune profile, rather than merely tolerating or ignoring the vaccine virus. The role of type I interferons is further underscored by studies in which HVT vaccination, particularly when co-administered with probiotic lactobacilli, enhances splenic IFN-α expression at 21 days post-infection and elevates IFN-β in cecal tonsils at 10 days post-infection, concurrently reducing expression of immunosuppressive TGF-β4 [8]. These data illustrate that the innate response to vaccination is not a fixed entity but can be modulated by adjuvants or co-administered immunomodulators, a finding with practical implications for vaccine formulation.

The importance of early interferon induction is also evident at the transcriptomic level. In ovo administration of an mRNA vaccine encoding MDV glycoprotein B (gB) and phosphoprotein 38 (pp38) rapidly activates STAT1 and ISGs such as MX1, OASL, and IFIT5 in the spleen within 12 to 48 hours, demonstrating that the innate response can be triggered independent of live viral replication [28]. This finding highlights that the immune response to MD vaccines is not solely reliant on the propagation of the vaccine virus itself but can be driven by antigenic stimulation of pattern recognition receptors. While mRNA vaccines are not yet standard in poultry practice, they provide a mechanistic benchmark for understanding how different vaccine platforms engage the innate immune system.

Adaptive Immune Responses: T Cell Subsets and the Th1 Trajectory

The protective efficacy of MD vaccines is predominantly mediated by cell-mediated immunity, with CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ Th1 cells playing central roles. Monovalent HVT vaccination induces a measurable expansion of CD8αhigh T cells, but the quality and breadth of this response are influenced by the vaccine strain and the host’s genetic background. CVI988/Rispens, the gold standard serotype 1 vaccine, elicits a particularly robust CD8+ T cell response. Microarray analyses of CVI988-vaccinated chickens reveal upregulation of T cell receptor (TCR) 1-related genes during the latent phase of infection, with flow cytometry confirming that the CD8αhigh TCR1+ subpopulation is specifically and significantly increased in vaccinated-challenged birds compared to unvaccinated-challenged controls [36]. This population, though not the majority in the spleen, appears to be primed by vaccination and selectively expanded upon challenge with virulent MDV. The data also indicate that CD8αhigh TCR2+ cells, the major CD8+ subset, are increased in vaccinated birds regardless of challenge status, suggesting that vaccination establishes a durable memory pool [36].

The magnitude of these T cell responses is tightly linked to the major histocompatibility complex (MHC) haplotype of the host. Chickens with the B21 haplotype (MD-resistant) generate significantly higher frequencies of IFN-γ-producing pp38- and Meq-specific T cells following vaccination and challenge compared to B19 haplotype chickens (MD-susceptible) [32]. Strikingly, vaccination does not induce or boost Meq-specific effector T cells in susceptible chickens, whereas it potently primes both pp38- and Meq-specific responses in resistant lines [32]. This genetic restriction of vaccine-induced immunity has profound implications for field efficacy, as commercial flocks are outbred and MHC diversity is substantial. The differential ability of vaccine strains to overcome this genetic bottleneck, by presenting epitopes that are broadly immunogenic across haplotypes, may determine the real-world success of a given vaccine formulation.

Bivalent vaccines appear to enhance T cell responses in a manner that transcends simple additive effects. The accelerated migration of T and NK cells into the spleen observed with HVT/SB1 in ovo vaccination suggests that the bivalent formulation creates a microenvironment conducive to more efficient T cell priming [1]. Furthermore, the coordinated downregulation of SOCS1 and SOCS3 removes key negative regulators of Th1 differentiation, potentially allowing for a more sustained and robust IFN-γ response [1]. This is clinically relevant because vv+MDV strains, such as the emerging DH/18 strain, actively suppress IFN-β and IFN-γ expression even in the face of vaccination, leading to breakthrough infection [3]. Vaccines that can counteract this immunosuppression through enhanced Th1 polarization and SOCS downregulation may confer a protective advantage.

The role of γδ T cells in MD vaccine immunity is an area of emerging interest. CVI988, rMd5-BACΔMeq, and CVI-LTR vaccines all protect against vv+MDV-induced tumors, but they differentially affect γδ T cell frequencies. In birds challenged with vv+MDV 686, CVI-LTR vaccination led to a reduction in γδ+ T cells, while CVI988 did not significantly alter this population [5]. The functional significance of γδ T cell modulation by different vaccine strains remains unclear, but given that these cells bridge innate and adaptive immunity and can exhibit direct cytotoxic activity against transformed cells, their differential regulation could contribute to the distinct protective profiles of these vaccines.

Antibody Responses and Humoral Immunity

While cell-mediated immunity is considered the primary correlate of protection against MD, humoral responses are not irrelevant. HVT vaccination induces antibodies against viral glycoproteins, and these antibodies can neutralize cell-free virus, potentially limiting early dissemination. However, the most compelling evidence for a humoral role comes from studies of vaccine-induced exosomes. Serum exosomes from CVI988-vaccinated and protected chickens (VEX) contain mRNAs mapping to the entire MDV genome, whereas exosomes from tumor-bearing birds (TEX) predominantly contain transcripts from the terminal and internal repeat long (TRL/IRL) regions [33]. These VEX exosomes are hypothesized to deliver viral antigens to antigen-presenting cells systemically, thereby sustaining long-term immune surveillance beyond the initial vaccine-induced response [33]. The microRNA (miRNA) cargo is equally revealing: VEX exosomes are enriched in tumor suppressor miRNAs, while TEX exosomes carry abundant oncomiRs from both cellular (miR-106a~363 cluster) and MDV-encoded miRNA clusters [33]. This suggests that the humoral component of vaccine immunity may operate at the level of systemic intercellular communication, with exosomes acting as vectors for antigen delivery and immune modulation.

Bivalent vaccines may further enhance this exosome-mediated immunity through their ability to maintain higher vaccine virus loads in peripheral tissues. In feather pulp, the combination of CVI988 and HVT (program B) shows significantly higher replication rates and a greater percentage of positive samples compared to programs using recombinant HVT vectors [19]. This sustained replication likely provides a continuous source of antigens and immunostimulatory exosomes, reinforcing both humoral and cell-mediated memory.

Synergistic Mechanisms of Bivalent Vaccines

The mechanistic basis for the well-documented synergism of bivalent HVT/SB1 vaccination lies in the immunological division of labor between the two components. HVT (serotype 3) induces a broad, early interferon response and establishes a Th1-biased microenvironment, while SB1 (serotype 2) contributes additional ISG induction and may present a distinct set of conserved epitopes that are not cross-reactive with serotype 1 MDV strains [1]. The additive gene expression effects for TLR3, IFN-γ, OASL, Mx1, NOS2A, and IL-1β in co-infected splenocytes [1] suggest that the two viruses act on partially overlapping signaling pathways, each amplifying the other's effects. This is not merely a case of increased antigenic load; it is a case of molecular synergy.

Furthermore, the distinct replication kinetics of HVT and SB1 may contribute to the temporal breadth of protection. HVT replicates robustly in the first week post-hatch, providing early antiviral pressure, while SB1 and CVI988 components persist and provide longer-term immunity [19, 38]. Early challenge with oncogenic MDV does not interfere with the DNA load of CVI988 or SB1 in feather pulp at 7 days of age, but can occasionally affect HVT replication [38]. This resilience of the bivalent components ensures that even if one vaccine virus is partially suppressed by early field virus exposure, the other can maintain protective immunity.

Immunological Evasion and Vaccine Resistance

The immune responses elicited by vaccines are not static; they are dynamically shaped by the evolving virulent strains they are meant to control. Highly virulent MDV strains have acquired mechanisms to subvert vaccine-induced immunity, and the nature of this immune evasion can differ between pathotypes. The DH/18 strain, for example, causes a more profound suppression of IFN-β and IFN-γ expression than AH/1807, and this inhibition persists even in vaccinated birds, enabling the virus to replicate unchecked and break through vaccination [3]. The protective index of CVI988 against DH/18 is only 61.1, compared to 94.1 against AH/1807, underscoring that vaccine efficacy is not a property of the vaccine alone but an interaction between the vaccine and the immunosuppressive capacity of the circulating strain [3].

The molecular basis of this evasion often involves mutations in the Meq oncoprotein. The CVI988 vaccine strain harbors unique polymorphisms in Meq, particularly A71S and K77E, which drastically impair its transcriptional regulatory activity and abolish virulence [4]. When these mutations are engineered into a very virulent RB-1B backbone, the resulting recombinant virus (rRB-1B_Meq71/77) fails to induce clinical signs or lymphomas, and instead elicits a robust expansion of CD8+ T and γδ T cells during early infection [4]. This demonstrates that the Meq protein is not merely an oncogene but a central modulator of host immune responses. Field strains that acquire mutations in Meq, such as those found in Tanzanian, Egyptian, and Chinese isolates, may alter the T cell epitopes presented to the host, facilitating immune escape [6, 29, 37]. The emergence of natural recombinants between vaccine (CVI988) and virulent strains [2] further complicates the landscape, as these recombinants can acquire the replication capacity of virulent strains while retaining some vaccine-derived genetic elements, potentially altering their immunogenicity.

The threat of vaccine-derived recombination is a growing concern. Live vaccines, because they replicate in the host, can act as genetic donors for recombination with co-infecting field strains, potentially generating novel pathogens [2]. This underscores the importance of understanding not only the immune responses elicited by monovalent and bivalent vaccines but also the immunoselective pressures they impose on the viral population. The World Organisation for Animal Health (WOAH) has recognized the economic impact of MDV and the need for improved vaccine strategies to address virulence evolution, while the FAO has emphasized the importance of surveillance for emergent MDV pathotypes in poultry production systems, particularly in regions with intensive vaccination.

The Unfolded Protein Response and Immunometabolic Crosstalk

A fascinating but underappreciated dimension of vaccine-induced immunity is the role of the unfolded protein response (UPR). Cell culture replication of virulent MDV strains, but not vaccine strains, activates the UPR at late stages of infection, as measured by increased GRP78/BiP expression, XBP1 splicing, and induction of its target gene EDEM1 [43]. The level of UPR activation correlates with pathotype, with vv+MDV inducing the strongest response. Importantly, the MDV oncoprotein Meq modulates UPR activation, and ATF6 is found activated in vv+MDV-induced primary lymphomas, suggesting a role in tumor progression [43]. The absence of UPR activation by vaccine strains may be a key safety feature, as it avoids the cellular stress and potential oncogenic signaling that could be triggered by a dysregulated UPR. However, this also means that vaccine strains do not elicit the same immunometabolic signals as virulent viruses, which may influence the quality of the immune response.

Transcriptomic profiling of the bursa of Fabricius following in ovo mRNA vaccination reveals persistent modulation of genes involved in metabolism and apoptosis, including CLPS, CTRB1, and DNASE1 [28]. This indicates that vaccine-induced immune activation is accompanied by tissue-specific metabolic reprogramming, a phenomenon that may be essential for supporting the energetic demands of an expanding lymphocyte population. The interplay between metabolic remodeling and immune function in the context of MD vaccination is an area ripe for further investigation, as it may identify targets for adjuvant development.

In summary, the immune responses elicited by monovalent and bivalent MD vaccine strains are characterized by distinct kinetics, molecular signatures, and cellular compositions. Bivalent vaccines leverage additive innate activation, Th1 polarization, and SOCS downregulation to create a more robust and durable protective state. However, this immunity is continuously challenged by evolving field strains that deploy sophisticated immunosuppressive mechanisms, particularly through Meq-mediated interference with the type I and type II interferon axes. The future of MD control will depend on vaccines that not only induce strong immune responses but are also designed to be resilient against viral countermeasures, whether through subunit design, vector engineering, or strategic combination with immunomodulatory adjuvants.

Bivalent and Recombinant Vaccine Strategies: HVT/SB-1 and HVT-LT/SB-1

The evolution of Marek’s disease virus (MDV) vaccination strategies from monovalent preparations to complex bivalent and recombinant formulations represents a critical adaptive response to the escalating virulence of field strains. Among the most empirically validated and widely deployed combinations in global poultry production are the bivalent vaccines comprising turkey herpesvirus (HVT, serotype 3) and SB-1 (serotype 2), as well as their recombinant derivatives, most notably HVT-LT/SB-1. These strategies are not merely additive in their protective capacity; rather, they exploit fundamental immunological synergies that have been elucidated through transcriptional profiling, immunophenotyping, and challenge studies over the past two decades. The World Organisation for Animal Health (WOAH) recognizes MD as a disease of significant economic consequence, and the deployment of bivalent vaccines has become a cornerstone of control programs in regions where very virulent (vv) and very virulent plus (vv+) MDV strains are endemic.

Mechanistic Basis for Synergistic Protection in HVT/SB-1 Vaccination

The bivalent combination of HVT and SB-1 confers protection that is demonstrably superior to either vaccine administered alone, a phenomenon that has been attributed to the induction of distinct and complementary arms of the host immune response. Neerukonda and colleagues (2019) provided seminal insights into this synergy through comprehensive transcriptional analyses of innate and acquired immune patterning elicited by these vaccines [1]. Using both ex vivo splenocyte infection models and in ovo vaccination of commercial broiler embryos, the authors demonstrated that HVT/SB-1 vaccination induces an additive effect on the expression of key interferon-stimulated genes (ISGs), including TLR3, IFN-γ, OASL, Mx1, NOS2A, and IL-1β [1]. This additive induction was not merely a quantitative increase in gene expression; it reflected a qualitative shift in the immune microenvironment. Specifically, HVT/SB-1 vaccination resulted in a coordinated induction of IL-12p40 concomitant with the downregulation of suppressors of cytokine signaling 1 and 3 (SOCS1 and SOCS3), a transcriptional signature indicative of classical M1 macrophage polarization and T-helper 1 (Th1) patterning [1]. This is a critical finding, as the Th1 axis is essential for controlling intracellular pathogens like MDV, and the suppression of SOCS molecules removes a key negative regulator of JAK-STAT signaling, thereby amplifying the antiviral state.

Furthermore, the bivalent vaccine appeared to accelerate immune maturation in ovo. Neerukonda et al. observed expression patterns suggesting the hastened migration of T cells and natural killer (NK) cells into the spleen of vaccinated embryos [1]. This early establishment of a cellular immune presence in a primary lymphoid organ is hypothesized to create a hostile microenvironment for invading MDV, effectively shortening the window of vulnerability between hatch and the maturation of adaptive immunity. The implication is that HVT/SB-1 does not simply provide two independent sources of antigenic stimulation; rather, the combination of a serotype 3 (HVT) and a serotype 2 (SB-1) virus creates a unique immunological context where the innate response is amplified, negative regulatory loops are attenuated, and the kinetics of cellular immune trafficking are accelerated. This mechanistic synergy explains why bivalent vaccines have historically provided superior protection against vvMDV strains compared to monovalent HVT or SB-1 programs.

The Recombinant HVT-LT/SB-1 Strategy: Expanding the Protective Umbrella

Building upon the success of the conventional HVT/SB-1 bivalent platform, the development of recombinant HVT vectors encoding immunoprotective transgenes from other avian pathogens has represented a major advancement in poultry vaccinology. The HVT-LT/SB-1 combination, where HVT-LT denotes a recombinant HVT vector expressing the hemagglutinin-neuraminidase (HN) or fusion (F) genes of Newcastle disease virus (NDV) and/or the VP2 gene of infectious bursal disease virus (IBDV), exemplifies a strategy of multi-pathogen protection without compromising MD-specific immunity. The transcriptional profiling work by Neerukonda et al. is particularly instructive here, as they directly compared the immune patterning induced by HVT/SB-1 with that of HVT-LT/SB-1 in an in ovo vaccination model [1]. Their data revealed that the recombinant HVT-LT/SB-1 combination induced patterns of innate and acquired immune gene expression that were remarkably similar to those of the conventional bivalent vaccine [1]. This is a non-trivial finding; it demonstrates that the insertion of foreign transgenes into the HVT genome does not fundamentally disrupt the virus’s ability to synergize with SB-1 to induce the protective Th1-biased, ISG-rich immune microenvironment.

The practical significance of this finding is underscored by the work of Hulten and colleagues (2020), who evaluated a double construct HVT-ND-IBD vaccine (a recombinant HVT expressing both the NDV F gene and the IBDV VP2 gene) in combination with Rispens CVI988 (a serotype 1 vaccine) [23]. While their study focused on the Rispens combination, the principle applies directly to the HVT-LT/SB-1 strategy: the recombinant HVT backbone retains its efficacy against MDV challenge (in this case, strain RB1B) while simultaneously conferring protection against velogenic NDV and very virulent IBDV [23]. The ability to combine these recombinant HVT vectors with SB-1 allows producers to maintain the synergistic MD protection of the bivalent platform while gaining the economic and logistical benefits of multivalent vaccination. This is particularly critical in regions where co-infections with MDV, NDV, and IBDV are common, as co-infection with immunosuppressive viruses like REV has been shown to dramatically reduce MD vaccine efficacy, with protective indices dropping by as much as 33.3 points [30].

In Ovo Vaccination and Immune Maturation

The route and timing of bivalent and recombinant vaccine administration are critical determinants of their success. In ovo vaccination at embryonic day 18 (ED18) has become the standard in many commercial broiler operations, and the work of Neerukonda et al. provides a molecular rationale for this practice [1]. Their data showed that in ovo vaccination with HVT/SB-1 or HVT-LT/SB-1 hastened immune maturation, with transcriptional evidence of accelerated T cell and NK cell migration into the spleen [1]. This is consistent with the broader literature on in ovo immunomodulation. For instance, Bavananthasivam and colleagues (2018) demonstrated that in ovo administration of Toll-like receptor (TLR) ligands encapsulated in PLGA nanoparticles could diminish tumor development following MDV challenge, suggesting that the embryonic immune system is highly plastic and responsive to immunostimulatory signals [35]. The bivalent and recombinant vaccines appear to exploit this plasticity, effectively “priming” the immune system before hatch so that a protective response is already underway when the chick encounters virulent MDV in the post-hatch environment.

This early priming is particularly important given the non-sterilizing nature of MD vaccines. As highlighted by multiple sources, current vaccines, including bivalent formulations, prevent clinical disease and tumor formation but do not prevent infection or superinfection by field strains [15, 20, 35]. This “leaky” immunity creates a selective pressure for the emergence of more virulent strains, a phenomenon that has been well-documented in the evolution of MDV from mild (m) to very virulent plus (vv+) pathotypes [15, 31]. The bivalent and recombinant strategies, by accelerating the onset of a robust cellular immune response, aim to minimize the window during which the virus can replicate to high titers and transmit, thereby theoretically reducing the evolutionary pressure for increased virulence. However, the continued emergence of vaccine-breaking strains, such as the Chinese isolate SS1901 which caused 100% mortality in SPF chickens despite CVI988 vaccination, underscores that even the most sophisticated bivalent strategies are not a panacea [29].

Differential Replication Dynamics and Vaccine Coverage

The efficacy of bivalent HVT/SB-1 and recombinant HVT-LT/SB-1 strategies is also influenced by the differential replication dynamics of the component viruses. Muniz and colleagues (2020) compared the replication of CVI988 (serotype 1) and HVT (serotype 3) components in feather tips across different vaccination programs in Brazil [19]. They found that the conventional combination of CVI988 + HVT (analogous in principle to HVT/SB-1) showed significantly higher replication rates and a greater percentage of vaccine coverage in feather pulp compared to programs using recombinant HVT vector vaccines [19]. Specifically, at 28 days post-vaccination, the mean log copy number of HVT was significantly higher in the conventional bivalent program compared to programs relying solely on recombinant HVT vectors [19]. This finding has direct implications for the HVT-LT/SB-1 strategy: while the recombinant HVT-LT vector is highly effective, its replication kinetics in vivo may differ from the parental HVT strain, potentially affecting the degree of synergy with SB-1. The data from Muniz et al. suggest that vaccine programs incorporating a conventional HVT component alongside SB-1 may achieve more robust early replication and broader tissue distribution, which could translate into superior protection against early MDV challenge [19].

Furthermore, the ability to monitor vaccine replication in the field has been enhanced by the development of sophisticated molecular diagnostic tools. Wu and colleagues (2023) developed a quadruplex real-time PCR assay capable of simultaneously differentiating and quantifying HVT, CVI988, and virulent MDV-1 strains [10]. Similarly, Zhang et al. (2026) established a multiplex PCR method targeting the meq gene (for MDV-1) and gB genes (for MDV-2 and HVT) to differentiate all three serotypes in a single reaction [21]. These tools are essential for evaluating the efficacy of bivalent and recombinant vaccination programs in the field. They allow veterinarians to confirm that both components of the bivalent vaccine (e.g., HVT and SB-1) are replicating adequately and that vaccine coverage is sufficient to protect the flock. The ability to distinguish vaccine strains from field strains is also critical for surveillance, as the emergence of natural recombinants between vaccine and virulent strains, a phenomenon documented by Zhang et al. (2022) in China, poses a significant biosafety concern [2]. These recombinant strains, which can carry the skeleton of the CVI988 vaccine with the unique short region of a virulent strain, can exhibit mild virulence but high replication capability, potentially acting as stepping stones to more pathogenic variants [2].

The Challenge of Antigenic Diversity and Vaccine Resistance

Despite the immunological sophistication of bivalent and recombinant strategies, the relentless evolution of MDV continues to challenge their efficacy. The meq oncogene, a key determinant of MDV virulence, exhibits considerable sequence diversity among field strains, and specific mutations are associated with the ability to overcome vaccine-induced immunity. Luo and colleagues (2025) characterized the highly pathogenic Chinese strain SS1901, which harbored mutations in Meq including K77E, D80Y, V115A, T139A, P176R, and P217A [29]. Critically, the bivalent combination of CVI988 and HVT provided the highest protection (86.7%) against this strain, outperforming either vaccine alone [29]. This finding reinforces the central tenet of the bivalent strategy: that combining different serotypes provides a broader antigenic repertoire and a more robust immune response that can better accommodate the genetic diversity of circulating field strains.

However, the protection afforded by bivalent vaccines is not absolute. The Tanzanian MDV strains characterized by Chengula and colleagues (2025) exhibited amino acid substitutions in the meq gene associated with increased virulence, and phylogenetic analysis showed clustering with highly virulent strains from Egypt, Israel, and China [6]. Similarly, the Nigerian field isolates studied by Patria et al. (2024) revealed a complex landscape of meq mutations, including an RB1B-like lineage co-circulating with a European Polen5-like lineage, as well as recombinants harboring combinations of these mutations [26]. The authors posited that the vaccine strategy itself may be directly selecting for these mutations, driving the evolution of a potential “very virulent plus plus” (vv++) pathotype [26]. This sobering possibility highlights the need for continuous innovation in vaccine design, including the development of next-generation recombinant vaccines that target conserved epitopes or employ novel mechanisms of action, such as the CRISPR/Cas9-based approaches being explored by Hagag and colleagues [20].

In conclusion, the bivalent HVT/SB-1 and recombinant HVT-LT/SB-1 strategies represent a high-water mark in applied avian immunology, leveraging synergistic interactions between serotypes to induce a rapid, Th1-biased, and broadly protective immune response. The transcriptional data from Neerukonda et al. provide a mechanistic framework for understanding this synergy, while field studies from around the world confirm the practical utility of these approaches in controlling MD in the face of evolving viral threats [1, 6, 19, 23, 29]. Yet, the continued emergence of vaccine-resistant strains and the documented potential for recombination between vaccine and field viruses serve as a stark reminder that the arms race between MDV and vaccinologists is far from over. The future of MD control will likely depend on integrating these bivalent and recombinant platforms with novel adjuvants, such as probiotic lactobacilli [8] or TLR ligands [35], and with next-generation technologies like mRNA vaccines [28] and gene-editing approaches [20] to achieve the elusive goal of sterilizing immunity.

Antiviral Activity of Natural Extracts Against Field and Vaccine Strains of Marek's Disease Virus

The relentless evolution of Marek’s disease virus (MDV) toward increased virulence, coupled with the non-sterilizing nature of current live-attenuated vaccines, has necessitated the exploration of adjunctive and alternative antiviral strategies. Among these, the investigation of natural plant-derived compounds as direct antiviral agents against both vaccine and field strains of MDV represents a promising, yet underexplored, frontier in poultry health management. While vaccination remains the cornerstone of MD control, the capacity of natural extracts to inhibit viral replication in vitro and potentially reduce viral burden in vivo offers a complementary approach that could mitigate vaccine-driven virulence evolution and enhance overall flock protection. The World Organisation for Animal Health (WOAH) recognizes MD as a critical poultry disease with substantial economic ramifications, and the identification of novel antiviral compounds aligns with global efforts to reduce reliance on chemotherapeutic agents and address antimicrobial resistance in food animal production.

Direct Plaque Reduction and Virucidal Activity Against Vaccine and Field Strains

The most direct evidence for the antiviral activity of natural extracts against MDV derives from plaque reduction assays, which quantitatively measure the ability of a compound to inhibit viral cytopathic effect in cell culture. A landmark study by Ewies et al. (2021) [25] systematically evaluated the antiviral efficacy of two widely available botanicals, Curcuma longa (curcumin) and Lagenaria siceraria (bottle gourd), against both a vaccine strain (herpesvirus of turkeys, HVT; serotype 3) and a vaccine-derived strain (Rispens/CVI988; serotype 1) of MDV. The experimental design employed a standard plaque reduction assay in which constant virus dilutions were pre-incubated with plant extracts prior to inoculation of permissive cell monolayers. Results demonstrated that curcumin exerted a potent, dose-dependent antiviral effect, achieving 80% plaque reduction (PR%) against HVT and 66% PR% against the Rispens strain at a 1:8 virus dilution. This differential susceptibility between serotypes is noteworthy; HVT, being a heterologous vaccine strain, may exhibit altered envelope glycoprotein composition or replication kinetics compared to the homologous serotype 1 Rispens strain, potentially affecting the accessibility of curcumin to viral targets. The pronounced activity of curcumin against HVT suggests that its mechanism may involve disruption of the viral envelope or inhibition of early entry events, as HVT is known to be more sensitive to physical and chemical inactivation than MDV serotype 1 strains.

In contrast, the bottle gourd extract demonstrated a more moderate antiviral action, yielding 40% PR% and 33% PR% against HVT and Rispens, respectively, at the same 1:8 dilution. This reduced efficacy compared to curcumin likely reflects differences in the concentration and bioavailability of active phytochemicals. Lagenaria siceraria contains a complex mixture of triterpenoids, flavonoids, and saponins, some of which have documented antiviral properties against enveloped viruses, but their concentration in crude aqueous or ethanolic extracts may be insufficient to achieve high-level MDV inhibition. Importantly, Ewies et al. [25] also validated the antiviral activity of these extracts against a recently isolated wild-type (field) MDV strain using quantitative real-time PCR with SYBR Green chemistry. The threshold cycle (Ct) values for curcumin-treated samples (26.1 ± 1.7) and bottle gourd-treated samples (25.62 ± 1.1) were significantly lower (indicating higher initial viral load reduction) than the positive control (17.125 ± 0.6). This PCR-based confirmation is critical, as plaque reduction assays primarily detect inhibition of infectious virus production, whereas PCR captures reductions in viral nucleic acid load, which may reflect both direct virucidal effects and inhibition of viral genome replication.

Mechanistic Considerations: Direct Virucidal versus Replication Inhibition

The differential activity observed between curcumin and bottle gourd extracts, as well as between vaccine and field strains, prompts a deeper examination of potential mechanisms. Curcumin, a polyphenolic compound derived from turmeric, is renowned for its broad-spectrum antiviral properties against numerous enveloped viruses, including influenza virus, herpes simplex virus, and hepatitis B virus. Its primary antiviral mechanism involves disruption of the viral lipid envelope, thereby preventing viral attachment and entry into host cells. Given that MDV, HVT, and all herpesviruses possess a lipid envelope, curcumin’s efficacy in plaque reduction assays is plausibly attributable to direct virucidal activity, i.e., irreversible inactivation of extracellular virions. This hypothesis is supported by the fact that pre-incubation of virus with curcumin, as performed in the standard assay, allows the compound to interact with the viral particle before host cell contact. The higher plaque reduction against HVT (80%) compared to Rispens (66%) may reflect structural differences in envelope lipid composition or glycoprotein density between the two strains. Furthermore, curcumin is known to inhibit the nuclear factor-kappa B (NF-κB) pathway, which is hijacked by MDV during lytic replication. If curcumin were to enter cells, it could theoretically also suppress MDV reactivation from latency by modulating the host cell signaling environment, although this remains speculative in the context of MDV.

The moderate activity of bottle gourd extract suggests a different, possibly less potent, mechanism. Lagenaria siceraria extracts have been reported to contain compounds that inhibit viral attachment or interfere with viral DNA polymerase activity. However, the relatively low PR% (33-40%) indicates that this extract may require higher concentrations or more prolonged exposure to achieve significant viral suppression. A critical consideration is the presence of tannins and other phenolic compounds in bottle gourd that can non-specifically bind to viral surface proteins, thereby blocking receptor interactions. Such mechanisms are inherently less specific than targeted inhibition of viral enzymes, which may account for the lower efficacy.

Implications for Vaccine Strain Integrity and Field Strain Control

The ability of natural extracts to inhibit both vaccine and field strains carries profound implications for MD control strategies. Live vaccines such as HVT and CVI988 are administered to billions of chickens annually, and they replicate extensively in the host to generate protective immunity. If natural extracts with antiviral activity were to be administered concurrently with or shortly after vaccination, there is a theoretical risk that they could suppress vaccine virus replication, thereby compromising the establishment of protective immunity. This concern is paramount given that vaccine replication in feather pulp is a known correlate of protective efficacy [19, 38]. However, the data from Ewies et al. [25] indicate that curcumin exhibits dose-dependent activity, and at lower concentrations, it may selectively inhibit field strains while sparing vaccine strains. For instance, at a 1:8 dilution, curcumin achieved 80% PR against HVT but only 66% against Rispens, suggesting that Rispens may be intrinsically more resistant to curcumin’s virucidal effects. This differential sensitivity could be exploited to design extract-based treatments that preferentially target virulent field viruses without unduly suppressing vaccine replication.

On the other hand, field strains isolated from vaccinated flocks often exhibit enhanced replication kinetics and greater resistance to host immune responses. The confirmation by Ewies et al. [25] that both curcumin and bottle gourd extracts reduced the nucleic acid load of a wild-type MDV strain (as measured by PCR) suggests that these extracts may be particularly valuable in reducing the environmental shedding of field viruses. This is critical because non-sterilizing vaccines permit field virus replication and shedding, driving the continuous evolution of more virulent strains [2, 3, 15]. By reducing the viral load in vaccinated birds, natural extracts could theoretically lower the selective pressure for vaccine resistance and slow the emergence of very virulent plus (vv+) or very virulent plus plus (vv++) pathotypes [26, 29]. Moreover, recent studies have documented the emergence of recombinant MDV strains that incorporate vaccine genome fragments into virulent backbones, a phenomenon known as vaccine-virulence recombination [2]. If natural extracts can reduce the replication of both vaccine and field viruses, they might reduce the frequency of co-infection events that facilitate such recombination, thereby enhancing the genetic stability of vaccine strains.

The Role of Natural Extracts in an Integrated Disease Management Framework

Beyond direct antiviral activity, the anti-inflammatory and immunomodulatory properties of curcumin and bottle gourd extracts may synergize with vaccine-induced immunity to provide enhanced protection. Neerukonda et al. (2019) [1] demonstrated that HVT and SB-1 vaccines induce a coordinated interferon (IFN) response and upregulation of IFN-stimulated genes (ISGs) such as OASL and Mx1 in splenocytes. Curcumin is a well-known activator of the Nrf2 pathway and an inhibitor of NF-κB, which could modulate the inflammatory milieu during the critical period of vaccine-induced immune activation. Specifically, curcumin’s ability to dampen excessive pro-inflammatory cytokine production (e.g., IL-1β, IL-6) while enhancing IFN-γ responses could potentially hasten the maturation of T-helper 1 (Th1) and cytotoxic T lymphocyte (CTL) responses following vaccination. The study by Bavananthasivam et al. (2021) [8] showed that concurrent administration of probiotic lactobacilli with HVT enhanced MHC class II expression and reduced tumor incidence, illustrating that adjunctive immunomodulatory agents can improve vaccine efficacy. Natural extracts with both antiviral and immunomodulatory properties may function analogously, providing a two-pronged attack: direct suppression of viral replication coupled with reinforcement of the host adaptive immune response.

It is also important to consider the practical aspects of delivering natural extracts in commercial poultry production. The use of crude plant extracts, while economical, presents challenges in terms of standardization of active compound concentration, palatability, and potential toxicity at high doses. The study by Ewies et al. [25] employed relatively unsophisticated extraction methods, and the observed antiviral activity was determined in vitro using cell culture systems. Extrapolation to in vivo efficacy requires careful pharmacokinetic studies, as the bioavailability of curcumin, in particular, is notoriously poor due to rapid glucuronidation and first-pass metabolism. However, emerging technologies such as poly(lactic-co-glycolic acid) (PLGA) nanoparticle encapsulation have been successfully employed to deliver toll-like receptor ligands (TLR-Ls) in ovo, achieving sustained release and enhanced immunogenicity [35]. Similar encapsulation strategies could be adapted for curcumin or other plant-derived antivirals to improve their stability and bioavailability in the avian gastrointestinal tract or via the in ovo route.

Future Directions and Knowledge Gaps

The current literature on natural antiviral activity against MDV remains sparse, with the study by Ewies et al. [25] representing one of the few systematic investigations. Significant knowledge gaps persist. First, the spectrum of activity against the full pathotype range, from mild to very virulent plus (vv+) strains, is unknown. Given the extensive genetic diversity among field strains, particularly in the meq oncogene [6, 26, 29, 37], it is plausible that some strains may possess resistance mechanisms to specific phytochemicals, analogous to the emergence of drug-resistant herpes simplex virus mutants. Second, the potential for synergistic or antagonistic interactions between natural extracts and live vaccine viruses has not been thoroughly investigated. Concurrent administration of curcumin with HVT could theoretically impair vaccine take, as suggested by the 80% plaque reduction observed against HVT in vitro. Conversely, the moderate effect of bottle gourd extract (40% PR) may be at a level compatible with adequate vaccine replication. Third, the stability of these extracts during the harsh conditions of feed processing or drinking water administration remains uncharacterized. Fourth, the immunomodulatory effects of these extracts on the ontogeny of MDV-specific CTL responses, as described by Sun et al. (2021) [34] and Boodhoo and Behboudi (2022) [32], have not been evaluated in the context of natural extract intervention. Finally, the ecological impact of introducing antiviral compounds into commercial poultry operations, particularly regarding selection pressure on non-target viral populations and the potential for horizontal gene transfer of resistance determinants, warrants careful risk assessment.

In conclusion, the antiviral activity of natural extracts, particularly curcumin, against both field and vaccine strains of MDV represents a promising avenue for augmenting existing MD control programs. The demonstration of dose-dependent plaque reduction and PCR-confirmed viral load reduction provides a robust foundation for further investigation. However, the transition from in vitro efficacy to practical in vivo application requires a concerted effort to optimize formulation, delivery, and safety, while ensuring that vaccine-induced protective immunity is not compromised. As the global poultry industry grapples with the inexorable evolution of MDV toward higher virulence, the integration of natural antiviral compounds into a comprehensive biosecurity and vaccination strategy may offer a sustainable and economically viable solution.

Future Directions in Marek's Disease Vaccine Development and Improved Protection

The relentless evolution of Marek's disease virus (MDV) towards greater virulence, driven in part by the non-sterilizing nature of current live vaccines, necessitates a paradigm shift in vaccine development. While the current gold standard, CVI988/Rispens, and bivalent combinations like HVT/SB-1 have provided remarkable economic relief, the emergence of very virulent plus (vv+) pathotypes and vaccine-breaking strains, such as those documented in China [3, 12, 29], Nigeria [26], and Tanzania [6], underscores the urgency for next-generation strategies. Future directions must move beyond empirical attenuation towards rational, mechanism-based design, leveraging insights from viral genomics, host immunology, and advanced biotechnological platforms. The path forward will be defined by three overarching imperatives: (1) engineering vaccines that induce sterilizing immunity or robust, broad-spectrum protection against evolving field strains; (2) developing novel adjuvants and delivery systems to enhance and shape the immune response; and (3) creating sophisticated diagnostic and surveillance tools to monitor vaccine efficacy and viral evolution in real-time.

Rational Design of Next-Generation Vaccine Platforms

The limitations of traditional live-attenuated vaccines, namely, their inability to block infection and replication, thereby permitting recombination with field strains [2], have spurred the development of genetically defined, safer, and more efficacious candidates. A primary focus is the precise manipulation of the viral oncogene meq. The CVI988 vaccine strain harbors unique polymorphisms in Meq, particularly A71S and K77E, which have been shown to abolish transcriptional regulatory activity and completely abrogate virulence when introduced into a very virulent RB-1B background [4]. This finding provides a molecular blueprint for creating attenuated vaccines with defined, stable mutations that preclude reversion to virulence. Furthermore, domain-swapping experiments between the Meq of Md5 (very virulent) and CVI988 have revealed that the DNA-binding domain is critical for tumor incidence, while the transcriptional regulatory domain influences tumor distribution and size [27]. This level of mechanistic understanding allows for the rational design of Meq-mutated viruses that are not only safe but also tailored to elicit specific protective immune profiles.

Beyond single-gene modifications, the deletion of multiple virulence-associated genes represents a promising avenue. The double deletion of meq and vIL-8 (686BAC-ΔMeqΔvIL8) has yielded a vaccine candidate that provides protection comparable to CVI988 against vv+ MDV challenge while significantly reducing the lymphoid organ atrophy associated with meq-null viruses [9]. This addresses a critical safety concern, as meq-deleted viruses, while protective, can cause immunosuppression in maternal antibody-negative chicks [18]. However, further attenuation, such as deletion of the viral thymidine kinase (tk) gene from a meq-deleted backbone, while reducing lymphoid atrophy, resulted in diminished protective efficacy compared to CVI988 [18]. This highlights the delicate balance between attenuation and immunogenicity, suggesting that a multi-gene deletion strategy must be carefully calibrated to preserve the virus's ability to replicate sufficiently to induce a robust, long-lasting immune response.

The use of recombinant viral vectors, particularly herpesvirus of turkeys (HVT), will continue to be a cornerstone of future MD vaccines. HVT offers a stable, safe platform that can accommodate large foreign DNA inserts, enabling the development of multivalent vaccines that protect against MDV and other major poultry pathogens simultaneously. The success of constructs like HVT-ND-IBD, which protects against Newcastle disease, infectious bursal disease, and MDV [23], demonstrates the immense potential of this platform. Future iterations will likely incorporate computationally optimized broadly reactive antigen (COBRA) sequences, as demonstrated for H5 avian influenza, to elicit cross-protective immunity against antigenically diverse MDV field strains [17]. This approach could preemptively address the continuous antigenic drift observed in the Meq protein [6, 26, 29, 37].

Harnessing Innate Immunity and Novel Adjuvants

A fundamental weakness of current MD vaccines is their reliance on a narrow adaptive immune response, primarily CD8+ T cells, while failing to prevent infection. Future strategies will focus on activating and directing the innate immune system to create a more hostile environment for MDV and to shape a more effective adaptive response. The in ovo administration of Toll-like receptor (TLR) ligands encapsulated in PLGA nanoparticles has shown remarkable promise. Encapsulated CpG (TLR21) and LPS (TLR4) ligands reduced tumor incidence by up to 60% in challenged chickens, likely through the induction of pro-inflammatory cytokines like IL-1β and IL-18 [35]. This approach provides a non-viral, chemical adjuvant strategy that can be used alone or in combination with traditional vaccines to bolster early protection.

Similarly, the administration of probiotic Lactobacillus species alongside HVT has been shown to enhance vaccine efficacy. This combination increased MHC II expression on antigen-presenting cells, reduced regulatory T cell populations, and halved tumor incidence compared to HVT alone [8]. The mechanism appears to involve a shift towards a Th1-type response, characterized by increased IFN-γ and IL-12p40 expression, and a downregulation of immunosuppressive cytokines like TGF-β4 [8]. These findings align with transcriptomic analyses of bivalent HVT/SB-1 vaccination, which also demonstrated a coordinated induction of IL-12p40 and suppression of SOCS1 and SOCS3, indicative of classical M1 macrophage and Th1 polarization [1]. Future vaccine formulations could be rationally designed to include specific TLR ligand combinations or defined bacterial consortia that synergize with the vaccine virus to accelerate immune maturation and establish a durable, cell-mediated memory response. The use of serum exosomes from vaccinated birds, which carry viral mRNAs and tumor-suppressor miRNAs, also presents a novel avenue for understanding and potentially augmenting systemic vaccine-induced immunity [33].

The Advent of mRNA and Gene-Editing Technologies

The COVID-19 pandemic validated the speed and flexibility of mRNA vaccine platforms. For MDV, this technology offers a transformative opportunity to overcome the limitations of live viral vaccines. A landmark study demonstrated that in ovo administration of a bivalent mRNA vaccine encoding MDV glycoprotein B (gB) and phosphoprotein 38 (pp38) rapidly activates distinct, tissue-specific transcriptional programs in the spleen and bursa of Fabricius [28]. The early upregulation of interferon-stimulated genes (MX1, OASL, IFIT5) and STAT1 in the spleen indicates a robust innate antiviral state, while metabolic and apoptotic remodeling in the bursa suggests a mechanism for preventing lymphoid atrophy [28]. This platform is inherently safe, as it cannot replicate or recombine with field strains, and it can be rapidly updated to encode antigens from newly emerging, vaccine-breaking strains. The primary challenge will be optimizing mRNA stability, delivery (e.g., lipid nanoparticles), and cost-effectiveness for the poultry industry.

In parallel, CRISPR/Cas9 technology offers a direct antiviral approach. Proof-of-concept studies have shown that targeting essential MDV genes with multiple guide RNAs can completely abrogate viral replication in cell culture, with no emergence of escape mutants [20]. While delivering this system in vivo to all susceptible cells in a chicken remains a formidable hurdle, it represents the ultimate goal of achieving sterilizing immunity. Future research may focus on developing transgenic chickens that constitutively express anti-MDV CRISPR components, or on using viral vectors (e.g., adeno-associated viruses) to deliver the system to target cells. This approach, if realized, could provide a genetic barrier to infection that is independent of the adaptive immune system and impervious to viral evolution.

Advanced Diagnostics and Genomic Surveillance

The success of any vaccination program is contingent upon the ability to monitor its efficacy and detect emerging threats. The continuous evolution of MDV, driven by vaccine-driven selection [31], demands sophisticated surveillance tools. The development of rapid, field-deployable diagnostics that can differentiate vaccine strains from virulent field strains is critical. Novel isothermal amplification methods, such as recombinase polymerase amplification (RPA) combined with CRISPR/Cas14a, allow for the visual detection of epidemic MDV-1 strains with high sensitivity (24.6 copies/μL) and specificity, without cross-reactivity with HVT or CVI988 [11]. Similarly, multiplex real-time PCR assays [10] and conventional multiplex PCR methods [21] have been developed to simultaneously detect and differentiate all three MDV serotypes, providing a comprehensive picture of the viral landscape in a flock.

These diagnostic tools must be integrated with genomic surveillance programs that track the emergence of virulence-associated mutations, particularly in the meq gene. Studies from around the world have identified a growing number of polymorphisms, such as K77E, D80Y, P217A, and R176A, that are associated with increased virulence and vaccine resistance [6, 26, 29, 37, 39]. The detection of natural recombinants between vaccine and virulent strains [2] and the identification of strains with divergent virulence and vaccine resistance profiles [12] highlight the dynamic and unpredictable nature of MDV evolution. The World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) recognize the economic threat of MDV, and a coordinated global surveillance network, analogous to those for influenza, is needed. By correlating specific genetic markers with pathotype and vaccine breakthrough potential, as identified in large-scale genomic studies [31], we can move towards a predictive model of MDV evolution. This would allow for the preemptive selection or design of vaccines that are effective against the strains most likely to become dominant, rather than reacting to outbreaks after they occur. The inherent intrastrain variation observed even in vaccine stocks like CVI988 [16] further emphasizes the need for rigorous quality control and deep sequencing of vaccine seeds to ensure genetic stability and consistent protective efficacy.

References

[1] Neerukonda S, Katneni UK, Bhandari N, Parcells M. Transcriptional Analyses of Innate and Acquired Immune Patterning Elicited by Marek's Disease Virus Vaccine Strains: Turkey Herpesvirus (HVT), Marek's Disease Virus 2 (strain SB1), and Bivalent Vaccines (HVT/SB1 and HVT-LT/SB1).. Avian diseases. 2019. DOI: https://doi.org/10.1637/AVIANDISEASES-D-19-00117

[2] Zhang Y, Lan X, Wang Y, Lin Y, Yu Z, Guo R, et al.. Emerging natural recombinant Marek's disease virus between vaccine and virulence strains and their pathogenicity.. Transboundary and Emerging Diseases. 2022. DOI: https://doi.org/10.1111/tbed.14506

[3] Yu Z, Zhang Y, Lan X, Wang Y, Guo R, Li K, et al.. Differences in Pathogenicity and Vaccine Resistance Discovered between Two Epidemic Strains of Marek’s Disease Virus in China. Viruses. 2023. DOI: https://doi.org/10.3390/v15040945

[4] Sato J, Motai Y, Yamagami S, Kurokawa A, Win SY, Horio F, et al.. Amino Acid Polymorphisms in the Basic Region of Meq of Vaccine Strain CVI988 Drastically Diminish the Virulence of Marek’s Disease Virus. Viruses. 2025. DOI: https://doi.org/10.3390/v17070907

[5] Khaled N, Gaghan C, Fares AM, Goodell C, Stanley W, Kulkarni R, et al.. Protection Conferred by Gallid Alphaherpesvirus 2 Vaccines Against Immunosuppression Induced by Very Virulent Plus (vv+) Marek’s Disease Virus Strains in Commercial Meat Type Chickens. Pathogens. 2025. DOI: https://doi.org/10.3390/pathogens14010054

[6] Chengula A, Mpete H, Makasali RJ. Surveillance and Molecular Characterization of Marek’s Disease Virus (MDV) Strains Circulating in Tanzania. Viruses. 2025. DOI: https://doi.org/10.3390/v17050698

[7] Baigent S, Nair V, Galludec HL. Real-time PCR for differential quantification of CVI988 vaccine virus and virulent strains of Marek’s disease virus. Journal of Virological Methods. 2016. DOI: https://doi.org/10.1016/j.jviromet.2016.03.002

[8] Bavananthasivam J, Alizadeh M, Astill J, Alqazlan N, Matsuyama-Kato A, Shojadoost B, et al.. Effects of administration of probiotic lactobacilli on immunity conferred by the herpesvirus of turkeys vaccine against challenge with a very virulent Marek's disease virus in chickens.. Vaccine. 2021. DOI: https://doi.org/10.1016/j.vaccine.2021.03.046

[9] Liao Y, Reddy S, Khan OA, Sun A, Lupiani B. A Novel Effective and Safe Vaccine for Prevention of Marek’s Disease Caused by Infection with a Very Virulent Plus (vv+) Marek’s Disease Virus. Vaccines. 2021. DOI: https://doi.org/10.3390/vaccines9020159

[10] Wu S, Ding T, Shao H, Qian K, Ye J, Qin A. A quadruplex real-time PCR assay combined with a conventional PCR for the differential detection of Marek’s disease virus vaccines and field strains. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1161441

[11] Zhu Z, Cui M, Liu Y, Yao X, Lu M, Wang M, et al.. CRISPR/Cas14a combined with RPA for visual detection of Marek’s disease virus. bioRxiv. 2025. DOI: https://doi.org/10.1128/spectrum.02625-25

[12] Sun G, Zhang Y, Lv H, Zhou L, Cui H, Gao Y, et al.. A Chinese Variant Marek’s Disease Virus Strain with Divergence between Virulence and Vaccine Resistance. Viruses. 2017. DOI: https://doi.org/10.3390/v9040071

[13] Lee S, Takagi M, Ohashi K, Sugimoto C, Onuma M. Difference in the meq gene between oncogenic and attenuated strains of Marek's disease virus serotype 1.. Journal of Veterinary Medical Science. 2000. DOI: https://doi.org/10.1292/JVMS.62.287

[14] Sadigh Y, Tahiri‐Alaoui A, Spatz S, Nair V, Ribeca P. Pervasive Differential Splicing in Marek’s Disease Virus Can Discriminate CVI-988 Vaccine Strain from RB-1B Very Virulent Strain in Chicken Embryonic Fibroblasts. bioRxiv. 2019. DOI: https://doi.org/10.1101/723114

[15] Bertzbach LD, Conradie AM, You Y, Kaufer B. Latest Insights into Marek’s Disease Virus Pathogenesis and Tumorigenesis. Cancers. 2020. DOI: https://doi.org/10.3390/cancers12030647

[16] Ortigas-Vásquez A, Pandey U, Renner DW, Bowen CD, Baigent S, Dunn JR, et al.. Comparative analysis of multiple consensus genomes of the same strain of Marek’s disease virus reveals intrastrain variation. bioRxiv. 2023. DOI: https://doi.org/10.1093/ve/veae047

[17] Bertran K, Kassa A, Criado MF, Nuñez IA, Lee D, Killmaster L, et al.. Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses.. Vaccine. 2021. DOI: https://doi.org/10.1016/j.vaccine.2021.02.075

[18] Conrad S, Oluwayinka E, Heidari M, Mays J, Dunn J. Deletion of the Viral Thymidine Kinase in a Meq-Deleted Recombinant Marek’s Disease Virus Reduces Lymphoid Atrophy but Is Less Protective. Microorganisms. 2021. DOI: https://doi.org/10.3390/microorganisms10010007

[19] Muniz E, Ito D, Rodrigues L, Salles G, Kraieski AL, Junior D, et al.. COMPARISON OF CVI AND HVT VACCINE STRAINS REPLICATION IN FEATHER TIPS IN DIFFERENT MAREK´S DISEASE VACCINATION PROGRAMS. Ars Veterinaria. 2020. DOI: https://doi.org/10.15361/2175-0106.2020v36n4p278-285

[20] Hagag IT, Wight D, Bartsch D, Sid H, Jordan I, Bertzbach LD, et al.. Abrogation of Marek’s disease virus replication using CRISPR/Cas9. Scientific Reports. 2020. DOI: https://doi.org/10.1038/s41598-020-67951-1

[21] Zhang W, Teng M, Zheng L, Shi B, Wang W, Li G, et al.. Development of a Multiplex PCR Method for Efficient Differential Diagnosis of Clinical Cases and Vaccine Immunization of Marek’s Disease. Viruses. 2026. DOI: https://doi.org/10.3390/v18040471

[22] Song C, Yang Y, Hu J, Yu S, Sun Y, Qiu X, et al.. Safety and Efficacy Evaluation of Recombinant Marek’s Disease Virus with REV-LTR. Vaccines. 2020. DOI: https://doi.org/10.3390/vaccines8030399

[23] Hulten MCWv, Cruz-Coy J, Gergen L, Pouwels H, Dam GTt, Verstegen I, et al.. Efficacy of a turkey herpesvirus double construct vaccine (HVT-ND-IBD) against challenge with different strains of Newcastle disease, infectious bursal disease and Marek’s disease viruses. Avian Pathology. 2020. DOI: https://doi.org/10.1080/03079457.2020.1828567

[24] Chang K, Lee S, Ohashi K, Ibrahim A, Onuma M. The detection of the meq gene in chicken infected with Marek's disease virus serotype 1.. Journal of Veterinary Medical Science. 2002. DOI: https://doi.org/10.1292/JVMS.64.413

[25] Ewies SS, Samir M, Arafa AA, Tamam SM, Madbouly HM. Antiviral Activity of Curcuma Longa and Bottle Gourd Extracts Against Field and Vaccine Strains of Marek’s Disease Virus. Advances in Animal and Veterinary Sciences. 2021. DOI: https://doi.org/10.17582/journal.aavs/2021/9.10.1525.1531

[26] Patria JN, Jwander L, Mbachu I, Parcells L, Ladman B, Trimpert J, et al.. The Meq Genes of Nigerian Marek’s Disease Virus (MDV) Field Isolates Contain Mutations Common to Both European and US High Virulence Strains. Viruses. 2024. DOI: https://doi.org/10.3390/v17010056

[27] Ajithdoss D, Liao Y, Reddy S, Lupiani B. Marek’s Disease Virus (MDV) Meq Oncoprotein Plays Distinct Roles in Tumor Incidence, Distribution, and Size. Viruses. 2025. DOI: https://doi.org/10.3390/v17020259

[28] Doost JS, Yitbarek A, Wootton S, Behboudi S, Sharif S. Transcriptomic profiling reveals early immune activation and metabolic remodeling in lymphoid tissues following in ovo Marek's disease virus mRNA vaccination in chickens.. Veterinary Immunology and Immunopathology. 2025. DOI: https://doi.org/10.1016/j.vetimm.2025.111052

[29] Luo Q, Li H, Ge Z, Chen Z, Chen R. The emergence of a highly pathogenic marek’s disease virus featuring newly identified mutations in Meq oncogene in Southern China. Virology Journal. 2025. DOI: https://doi.org/10.1186/s12985-025-02931-3

[30] Sun G, Zhang Y, Zhou L, Lv H, Zhang F, Li K, et al.. Co-Infection with Marek’s Disease Virus and Reticuloendotheliosis Virus Increases Illness Severity and Reduces Marek’s Disease Vaccine Efficacy. Viruses. 2017. DOI: https://doi.org/10.3390/v9060158

[31] Dunn J, Pyrkosz AB, Steep A, Cheng HH. Identification of Marek's disease virus genes associated with virulence of US strains.. Journal of General Virology. 2019. DOI: https://doi.org/10.1099/jgv.0.001288

[32] Boodhoo N, Behboudi S. Differential Virus-Specific IFN-Gamma Producing T Cell Responses to Marek’s Disease Virus in Chickens With B19 and B21 MHC Haplotypes. Frontiers in Immunology. 2022. DOI: https://doi.org/10.3389/fimmu.2021.784359

[33] Neerukonda S, Tavlarides-Hontz P, McCarthy F, Pendarvis K, Parcells M. Comparison of the Transcriptomes and Proteomes of Serum Exosomes from Marek’s Disease Virus-Vaccinated and Protected and Lymphoma-Bearing Chickens. Genes. 2019. DOI: https://doi.org/10.3390/genes10020116

[34] Sun B, Wang Y, Wang Z, Lu S, Xia C. Structural and immunological identification and antiviral infection experiment of the dominant cytotoxic T lymphocyte epitopes of the oncogenic Marek’s disease virus. bioRxiv. 2021. DOI: https://doi.org/10.1101/2021.01.25.428198

[35] Bavananthasivam J, Alkie T, Astill J, Abdul-Careem MF, Wootton S, Behboudi S, et al.. In ovo administration of Toll-like receptor ligands encapsulated in PLGA nanoparticles impede tumor development in chickens infected with Marek's disease virus.. Vaccine. 2018. DOI: https://doi.org/10.1016/j.vaccine.2018.05.091

[36] Kano R, Konnai S, Onuma M, Ohashi K. Microarray analysis of host immune responses to Marek's disease virus infection in vaccinated chickens.. Journal of Veterinary Medical Science. 2009. DOI: https://doi.org/10.1292/JVMS.71.603

[37] Yehia N, El-Sayed HS, Omar SE, Erfan A, Amer F. Genetic evolution of Marek’s disease virus in vaccinated poultry farms. Veterinary World. 2021. DOI: https://doi.org/10.14202/vetworld.2021.1342-1353

[38] Thiemann TBR, Correa M, Cortes AL, Gimeno I. Early Challenge with Oncogenic Marek's Disease Virus Does Not Interfere with Load of Marek's Disease Vaccines DNA in the Feather Pulp at 7 Days of Age.. Avian diseases. 2022. DOI: https://doi.org/10.1637/21-00112

[39] Yılmaz A, Turan N, Bayraktar E, Tali H, Aydin O, Umar S, et al.. Molecular characterisation and phylogenetic analysis of Marek’s disease virus in Turkish layer chickens. British Poultry Science. 2020. DOI: https://doi.org/10.1080/00071668.2020.1758301

[40] Li H, Ge Z, Luo Q, Fu Q, Chen R. A Highly Pathogenic Marek’s Disease Virus Isolated From a Immunized to Bivalent Vaccines Chicken Farm in China. . 2021. DOI: https://doi.org/10.21203/rs.3.rs-933666/v1

[41] Dunn J, Mays J, Hearn C, Hartman A. Comparison of Marek's Disease Virus Challenge Strains and Bird Types for Vaccine Licensing. Avian diseases. 2021. DOI: https://doi.org/10.1637/aviandiseases-D-20-00122

[42] Qadoori MA, Hameed SS. MOLECULAR DETECTION OF PATHOTYPE OF MAREK’S DISEASE VIRUS IN LAYERS CHICKEN IN IRAQ. IRAQI JOURNAL OF AGRICULTURAL SCIENCES. 2025. DOI: https://doi.org/10.36103/44cryk81

[43] Neerukonda S, Katneni UK, Bott M, Golovan S, Parcells M. Induction of the unfolded protein response (UPR) during Marek's disease virus (MDV) infection.. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2018.06.016